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ABRSTRACT 
 
          Heparin, a highly sulfated glycosaminoglycan (GAG), is used extensively as an 
anticoagulant. It consists of repeating disaccharide units, containing iduronic acid (or 
glucuronic acid) and glucosamine, exhibiting variable degrees of sulfation. Heparin, and 
its analogues, are used during surgery and dialysis, and are often used to coat indwelling 
catheters and other devices where the vascular system is exposed. Administered 
parenterally, often continuously due to its short half-life, over 0.5 billion doses are 
required per year. Heparin is currently obtained from mucosal tissue of meat animals, 
mainly porcine intestine, and to a lesser extent bovine and ovine sources. The early stages 
of production are poorly controlled, due to the source of the material. This problem came 
into sharp focus in 2008 when the presence of contaminating over-sulfated chondroitin 
sulfate in heparin sourced from China resulted in almost 100 deaths in the USA. Coupled 
with the fact that only a few doses are obtained from each animal and due to cultural and 
religious reasons in some countries, alternative and well controlled sources of heparins 
are needed. The FDA and other regulatory agencies are currently considering the 
introduction of bovine and ovine unfractionated heparins. Worldwide, there are 1.4 
billion cattle, 1.9 billion sheep and goats and 980 million pigs. Both cow and sheep 
provide potential alternate sources of porcine heparin. Nowadays, with the advances in 
technology and manufacturing processes, higher quality bovine and ovine heparins are 
xxi 
 
now available in various part of the world and have been shown to exhibit similar 
biologic and clinical profiles compared to porcine one.  
 In this dissertation, we focused on determining the extent of biosimilarity 
between BMH, OMH and PMH. And how differences in molecular weight and strcturual 
composition may affect the pharmacological activity of these agents. Ten batches of each 
heparin were used throughout this project. These studies have shown that BMH, OMH 
and PMH exhibit comparable molecular profiles. However, BMH showed weaker 
anticoagulant and antiprotease activities compared to OMH and PMH. The neutralization 
profiles of all heparins were comparable at the same concentrations. Studies in platelet 
based systems showed that the HIT antibody interactions among heparins from different 
species were comparable. In Vivo studies in animal model showed that, the anti-Xa and 
anti-IIa effects of OMH and PMH were significantly stronger compared to BMH after IV 
administration. However, BMH showed significantly longer half -life (T1/2) compared to 
PMH and OMH with no major variations in AUC, Vd and CL parameters between each 
agent. 
In conclusion, these studies show that OMH and PMH are biosimilar and can be 
developed as such for clinical purposes. The bovine derived heparins exhibited slightly 
weaker potencies in functional assays despite comparable molecular profile. Potency 
adjustment for in vivo usage may be required to obtain comparable anticoagulant 
responses for the BMH. Soon, BMH and OMH may fill an unmet need not only for the 
Eastern world but also for Western countries as a potential alternate source of heparin.  
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CHAPTER ONE 
REVIEW OF LITERATURE 
Hemostasis & Coagulation 
 
 
Blood carries oxygen and nutrients to the various tissues of the body through a 
complex network of blood vessels. Injuries of blood vessels may cause disruption to 
the integrity of our vascular system. The ability of the body to respond to such an 
injury is known as hemostasis. Hemostasis is the process by which blood changes 
from a liquid to a gel, forming a clot to stop bleeding and to keep the blood within a 
damaged vessel. This process involves vascular constriction, platelet plug formation, 
and coagulation of the blood. 
Vascular constriction, or vasoconstriction, is the first response to a blood 
vessel injury. Many factors are involved in vasoconstriction including direct injury to 
the vascular smooth muscle, reflexes initiated by local pain receptors, and chemicals 
released by endothelial cells and platelets such as von Willebrand factor, ADP, and 
thromboxane. Vasoconstriction alone can significantly reduce blood loss for 20-30 
minutes, providing time for the formation of a platelet plug and blood clot. Various 
platelet adhesive proteins and activators participate in platelet plug formation. Von 
Willebrand factor (vWF) is a platelet adhesive protein which interacts with other 
adhesive proteins and activators like collagen, factor VIII, and other clotting factors. 
Circulating platelets bind to collagen via the glycoprotein Ia/IIa receptors located on 
their surface. Additional circulating vWF further strengthens this adhesion by forming 
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additional links between the platelets and the collagen fibrils. This adhesion 
process activates the platelets (Sakariassen et al., 1979). 
Platelets contain two different storage granules, α and β (dense). The α storage 
granules contain platelet derived growth factor (PDGF), fibrinogen, fibronectin, 
platelet factor 4 (PF4), β-thromboglobulin, thrombospondin-1, factor V, platelet 
activating factor (PAF), and von Willebrand factor (vWF) (Kaplan et al., 1987). The β 
granules contain ADP, ATP, histamine, calcium, and serotonin (5-HT2) (Verhoeven 
et., 1987). Once platelets are activated, the contents of α and β granules can be 
released. The contents of these granules cause various actions such as further platelet 
aggregation, activation of additional circulating platelets, and promotion of 
coagulation. Aggregating agents, or agonists, found in the circulation, as well as those 
released from the platelets themselves, induce further release of the platelet storage 
granule contents. Some of these agonists include ADP, collagen, thrombin, 
thromboxane (TXA2), PAF, serotonin, epinephrine, fibrinogen, and immune 
complexes (Packham, 1994). 
Platelet membranes express a variety of receptors for several agonists 
including, the TXA2 receptor, the 5-HT2 receptor, α2-adrenergic receptor, and the 
thrombin receptor. Additionally, a number of glycoproteins also present on the 
membrane surface serve as receptors for vWF (GP Ib), collagen (GP Ia/IIa), 
fibronectin (GP IIb/IIIa), and fibrinogen (GP IIb/IIIa) (Hourani et al., 1991). 
After platelets activate, they begin to aggregate on the injury site through 
fibrinogen bridges, which link glycoprotein IIb/IIIa receptors located on adjacent 
platelets. These aggregating platelets create a platelet mesh or plug. Although the 
platelet plug initially arrests blood loss, a fibrin based clot is necessary in order to 
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stabilize the mesh and allow it to survive the sheer force of blood flow. This occurs 
with the help of the coagulation system. 
Coagulation is a complex process consisting of the extrinsic, intrinsic, and 
common pathways. The extrinsic pathway, or tissue factor pathway, is activated when 
the endothelial lining of blood vessels is damaged, which can result from a cut, other 
abrasive injuries, or even the rupture of atherosclerotic plaques (Davie, et al., 1991. 
The opening in the injured vessel wall exposes tissue factor (TF), a cell surface 
glycoprotein, to flowing blood. TF is expressed by sub-endothelial cells, cells 
surrounding blood vessels, which are not normally exposed to circulating blood and 
white blood cells (WBC). TF is the cell surface receptor for the serine protease factor 
VIIa (FVIIa). Exposure of TF to blood allows for the formation of an activated 
TF/FVIIa complex. This TF/FVIIa complex then converts the inactive protease FX 
into the active protease FXa (Davie, et al., 1991. 
On the other hand, an amplification waterfall activates the serine proteases of 
the intrinsic (contact) pathway. Activation of the contact pathway is initiated with the 
formation of a complex composed of high-molecular-weight kininogen (HMWK), 
prekallikrein, and factor XII (FXII) on a collagen backbone (Kaplan et al., 1987). 
Both prekallikrein and FXII are converted to their active forms by the formation of 
this complex. FXIIa then converts FXI into FXIa, which then activates FIX. Factor 
IXa, along with its co-factor FVIIIa, form the tenase complex with the substrate, FX. 
The formation of this complex leads to the activation of FX to FXa. 
Both the extrinsic and intrinsic pathways of coagulation converge at the 
common pathway and cause the activation of FX to FXa (Figure 1). Factor Xa is the 
final enzyme required for the conversion of prothrombin to its active form, thrombin. 
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Activation of one molecule of FX leads to activation of thousands of prothrombin 
enzymes. This process occurs when FXa complexes with its co-factor, factor V, and 
Ca2+on a phospholipid surface to form the prothrombinase complex (Davie, et al., 
1991). Thrombin, or FIIa, is undoubtedly the most important enzyme in the 
coagulation cascade. Thrombin’s most critical function in the coagulation cascade is 
the conversion of soluble fibrinogen into insoluble strands of fibrin which are the 
building blocks for the hemostatic plug or mesh. However, thrombin has many other 
functions that are also important for maintaining hemostasis. Firstly, thrombin acts to 
convert factor XI to XIa, VIII to VIIIa, and V to Va; these are positive feedback 
mechanisms by which amplification of the cascade can occur. Secondly, thrombin can 
also activate factor XIII to XIIIa (FXIIIa) which increases the stability of the fibrin 
clot by crosslinking fibrin polymers. Finally, thrombin promotes platelet activation 
and aggregation by activating protease-activated receptors on platelet membranes. 
Fibrinogen is a plasma glycoprotein that is converted by thrombin into fibrin 
during the coagulation process. Cleavage of fibrinogen by thrombin results in the 
conversion of fibrinogen to fibrin and the consequent formation of a fibrin clot. Both 
fibrinogen and fibrin have various roles in coagulation, fibrinolysis, and inflammatory 
responses (Mosesson et al., 2005). These functions are regulated by interactive sites 
on fibrin/fibrinogen that are unmasked by the conversion of fibrinogen to fibrin 
(Mosesson et al., 2005). Fibrinolysis is a process that results in the removal of the 
fibrin-based clot, leading to fibrin degradation products and clot lysis. This process 
occurs following the conversion of plasminogen to plasmin by tissue-type 
plasminogen activator (tPA). Fibrinolysis is important for the restoration of normal 
blood flow. 
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Coagulation cascade 
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Figure 1. The coagulation cascade consists of several different zymogens, cofactors, 
and inhibitors. There are two primary pathways, the intrinsic and extrinsic, which lead 
to the common pathway and, ultimately, the activation of thrombin. Thrombin 
converts fibrinogen to fibrin forming a clot. In addition, thrombin converts factor XIII 
to factor XIIIa, which stabilizes the fibrin clot. 
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Heparin background 
Heparins discovery 
Heparin was first used in the early 20th century as an anticoagulant. The 
controversy surrounding its discovery stems back to 1916 when a medical student 
named Jay McLean isolated a fat soluble anticoagulant compound (phosphatides) 
from the dog livers. This took place in the laboratory of William Henry Howell 
(Couch, 1989; Marcum, 2000; McLean, 1959). In 1918, Dr. Howell termed this 
assumed phosphatide “heparin” to reflect its origin (Fye, 1984; Marcum, 2000).   
However, by 1922, Dr. Howell’s research determined that heparin was actually a 
carbohydrate and not a phosphatide as originally assumed (Howell, 1928). That same 
year, heparin became commercially available by a company known as Hynson, 
Westcott & Dunning (Fye, 1984). In the early 1930s, Howell began studying the 
effects of heparin in humans and those studies were continued throughout the 1930s 
by other laboratories (Fye, 1984). Until today, heparin continues to be used for the 
treatment and prophylaxis of a variety of thrombotic related diseases (Richard 
Norman, 2011).  
Unfractionated heparin (UFH) belongs to a family of long unbranched 
polysaccharides known as glycosaminoglycans (GAGs). UFH is highly ionized 
(strongly acidic) and has the highest negative charge density of any known biological 
molecule. It is comprised of repeating units of sulfated glucosamine and uronic acid 
(either iduronic or glucuronic) connected by 1 – 4 linkages. The major sites of 
sulfation are the 2-N and 6-O positions on glucosamine residues and the 2-O position 
on iduronate residues. The mean degree of sulfation is about 2.0-2.5 per disaccharide 
unit (Razi and Lindaht, 1995). 
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UFH is comprised of components that vary in molecular weight from 2 – 40 
kDa. It is a heterogeneous polymer with several different biological functions, 
including inhibition of blood coagulation, inhibition of platelet aggregation, release of 
tissue factor pathway inhibitor, and plasma clearing effects.  
Structure of heparin 
 
 
Figure 2. (A) Heparin composed of repeating disaccharide units of D-glycosamine 
and uronic acid linked by 1→4 interglycosidic bonds. The uronic acid residue could 
be either D-glucuronic acid or L-iduronic acid. (B) is the pentasaccharide sequence 
required for antithrombin binding (AT). 
 
 
Heparin sources 
 
          Heparin (UFH) is manufactured from either lung or intestinal animal 
mucosa. It is now primarily sourced from porcine intestines rather than from 
canine livers. In the past, bovine lung and ovine intestines were also alternative 
heparin sources (Fu et al., 2013). Porcine intestinal heparin officially replaced 
bovine lung heparin after the adoption of the 3rd International Standard by the 
World Health Organization in 1973, which dictated heparin to be porcine mucosal 
in origin (Mulloy et al., 2000). The use of ovine and bovine heparins is fairly 
limited around the world. The main use of bovine lung and intestinal heparins is in 
the Middle East, whereas ovine intestinal heparin has been used in Asia (Jasper et 
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al., 2015). Porcine intestinal heparin is now used by the rest of the world. This 
shift towards the use of porcine intestinal heparin was primarily due to concerns 
of bovine spongiform encephalopathy (BSE) and scrapie through the parental use 
of heparin derived from infected animals. Recently, there have been attempts to 
generate bioengineered heparin. A biosynthetic pathway that begins with bacterial 
synthesis of the backbone structure has been designed by some pharmaceutical 
organizations. To convert the extracted and purified heparosan to heparin, a series 
of chemoenzymatic modifications are performed to the polysaccharide backbone 
(Restaino et al., 2013). 
     Because porcine heparin is primarily used around the world, the risk of 
shortages and the cost of heparin has increased. (Fu, L., et al., 2013). Moreover, 
due to cultural and religious reasons in some countries, there is a large demand for 
alternative sources of heparins. Worldwide, it is estimated that there are 1.4 billion 
cattle, 1.9 billion sheep and goats, and 980 million pigs. With advances in 
technology and manufacturing processes, higher quality bovine and ovine 
heparins are now available. Additionally, biological contaminants such as BSE 
can be eliminated. Currently, bovine and ovine heparins are used in various parts 
of the world and have been shown to exhibit similar biological and clinical 
profiles (Jasper, J.P., et al 2015). The US FDA and other regulatory agencies are 
currently reviewing the possibility of substituting porcine heparin with heparin 
from other sources. Several Brazilian and Chinese manufacturers produce bovine 
and ovine heparins for clinical use. Bovine and ovine heparins have the potential 
to fill an unmet need not only for people with religious constrains but may also 
provide an alternate source of heparin in worldwide. 
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Heparin uses 
In 1937, heparin was determined to be highly effective in preventing 
postoperative thrombosis (Crafoord, 1937). Later, indications were extended to the 
treatment of established venous thrombosis and pulmonary embolism (Barritt et al., 
1960). Currently, it is used to prevent blood clots after surgery, during dialysis, and 
during blood transfusions. The main clinical indications for heparin are in the 
prevention and treatment of arterial and venous thromboembolism, thrombotic stroke, 
and in certain types of coronary artery syndrome, mainly unstable angina (Hirsh et al., 
2001). Heparin has well-known common side effects such as bleeding, heparin-
induced thrombocytopenia (HIT), and, to a lesser extent, skin necrosis and 
osteoporosis (Gray et al., 2008).  
Heparin mechanisms of action 
UFH mainly mediates its anticoagulant effect through antithrombin (AT). In 
1939, heparin was shown to mediate its biological functions through a plasma protein, 
known at that time as heparin cofactor. The suggestion that heparin cofactor may 
actually be antithrombin (AT) was made in the 1950s by Seegar at Wayne State 
University and Fitzgerald at MIT (Petitou, 2003). It was not until 1968 when 
Abildgaard (1968) isolated the plasma component, that the heparin cofactor was 
renamed antithrombin (Verstraete, 1990). Rosenberg and his colleagues then 
confirmed that AT was indeed the true heparin cofactor (Rosenberg et al., 1973; 
Rosenberg, 1975). 
 AT is a globular glycoprotein produced by the liver that consists of 432 
amino acids with a molecular weight of 58 kDa (Choay, 1989). It is a serine protease 
inhibitor (SERPIN) and is considered one of the most important anticoagulant 
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molecules in mammalian circulatory systems. The main targets of AT are thrombin 
and factor Xa; however, AT can inhibit several other serine proteases including IXa, 
XIa, XIIa, kallikrein, and plasmin. AT binds thrombin in a 1:1 stoichiometric 
complex (Rosenberg et al, 1973). The presence of heparin causes an approximate 
1000-fold increase in the rate of thrombin inactivation by AT (Bary et al., 1989). The 
interaction between AT and heparin (Figure 3) is dependent on a well-defined unique 
pentasaccharide sequence within heparin (Choay et al., 1983; Walenga et al., 1988; 
Petitou et al., 2003). The AT/heparin interaction produces a conformational change in 
the structure of AT. This change enables additional interactions between AT and 
heparin, resulting in a stronger binding (Pike et al., 2005). After the complex is 
formed, the AT interaction reverts to low-affinity binding resulting in the release of 
heparin from the covalent AT–factor Xa complex.  
        Thrombin inhibition occurs through a template mechanism of activation, 
whereby both AT and thrombin bind adjacently on the same heparin chain. Lane et al. 
(1984) demonstrated that a minimum heparin chain length of 18 saccharides (the 
pentasaccharide sequence and an additional adjacent 13 saccharides) is required for 
thrombin inhibition by AT. Negative charges available at the extended heparin 
polysaccharide units bind non-specifically to the exosite (positively charged region) 
of thrombin (Olson et al., 1992; Quinsey et al., 2004). A strong ternary complex 
between AT, thrombin, and heparin is formed. This complex produces a substantial 
increase in the rate of inhibition of thrombin. Due to the random distribution of the 
pentasaccharide sequence in heparin, lower MW fragments of heparin are not be able 
to bind to or inhibit thrombin. Thus, heparin chains in the MW range of 5 – 10 kDa 
have a progressive increase in thrombin inhibitory activity (Gray et al., 2008). 
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       Besides interactions with AT, heparin can also interact with another SERPIN 
known as heparin cofactor II (HCII). HCII has considerable sequence homology to 
AT. HCII consists of a single-chain glycoprotein which is 480 amino acids in length 
(Tollefsen, 1995). Unlike AT, HCII can only inhibit thrombin, with which it forms a 
1:1 stoichiometric complex (Tollefsen et al., 1982). Moreover, HCII can inhibit the 
proteolytic enzyme, chymotrypsin (Griffith et al., 1985). Heparin catalyzes the 
formation of the HCII-thrombin complex, which increases the rate of thrombin 
inhibition ~1000-fold (Tollefsen et al., 1981; Tollefsen et al., 1982; Griffith et al., 
1985).  
         Heparin also releases tissue factor pathway inhibitor (TFPI). TF is the main 
mediator by which thrombin generation is initiated in response to vessel damage 
(extrinsic pathway) (Mackman, 2006). TF is a 45 kDa transmembrane glycoprotein 
which is located at extravascular sites that are not normally exposed to the blood 
(Maroney et al., 2008). Heparin has been shown to release the pool of TFPI that is 
bound to glycosaminoglycan on the surface of the endothelium (Sandset et al., 1988). 
Additionally, heparin also upregulates TFPI gene expression which causes the 
elevation of both plasma and cellular TFPI pools (Crawley et al., 2008).  
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Antithrombin/ Heparin binding 
 
                                                                                                                                  Jeffrey I. Weitz, M.D. N Engl J Med 1997 
 
Figure 3. The main targets of AT are thrombin and factor Xa of the coagulation 
cascade. The interaction between AT and heparin is dependent on a well-defined 
unique pentasaccharide sequence within heparin. The AT/heparin interaction 
produces a conformational change in the structure of AT, enabling additional 
interactions between AT and heparin, resulting in stronger binding. The strong 
inhibition of thrombin is due to a template mechanism of activation, whereby both AT 
and thrombin bind adjacently on the same heparin chain. A minimum heparin chain 
length of 18 saccharides is required for thrombin inhibition by AT. The AT/heparin 
interaction produces a conformational change in the structure of AT. This 
conformational activation mechanism promotes binding of AT to the active site of 
factor Xa. 
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Heparin structural analysis 
Heparin has a complex molecular structure. The chemical profile plays a 
pivotal role in determining the biological activity of heparin (Barrowcliffe 1995). 
Various laboratory methods have been developed to analyze the structural elements of 
heparin. These include: gel permeation chromatography, scanning UV spectroscopy, 
heparinase digestion, mass spectrometry, and nuclear magnetic resonance 
spectroscopy. All are useful tools to understand the underlying structure-activity 
relationship of heparins. 
The molecular weight of heparin is one of the most important determinants for 
its biological activity and bioavailability (Emanuele and Fareed, 1987). Gel 
permeation chromatography high performance liquid chromatography (GPC-HPLC) 
is usually used to determine number average molecular weight (Mn), weight average 
molecular weight (Mw), and polydispersity (Ahsan et al, 1994). Additional methods 
such as viscometry, ultracentrifugation, and gradient polyacrylamide gel 
electrophoresis (PAGE) can be used for further analysis of the molecular weight 
profile of heparin (Linhardt et al. 1988). 
         High-resolution analysis of heparin structure has relied on spectroscopic 
methods such as proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) 
spectroscopy (Casu and Torri 1999.). NMR spectroscopy is used to determine the 
ratio of iduronic acid to glucuronic acid, the content of N-acetyl-glucosamine, and the 
patterns and degree of sulfation. Considering its wide breadth of analysis NMR 
spectroscopy has emerged as an indispensable method for the detection and 
identification of both structural heterogeneities within and between heparin samples, 
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as well as for the detection and identification of contaminants (Monakhova et al., 
2015). 
Heparin pharmacokinetics 
Unfractionated heparin is a heterogeneous mixture of polysaccharide chains of 
varying length. It is usually administered by continuous IV infusion or SC injection. 
To overcome the low bioavailability associated with the SC route, a higher initial 
dose of heparin is required (Hull et al., 1986). After bolus IV injection, UFH has a 
half-life of approximately 1-2 hours (Eikelhoom and Hankey, 2002), a volume of 
distribution of 40-70 ml/kg (Spruill et al., 2001), and it is eliminated from the blood 
exponentially (Blombäck et al., 1963). Such first-order kinetics would ordinarily 
suggest a constant half-life of the drug, which is independent to the amount of drug 
injected. However, it is well known that the half-life of UFH increases in relation to 
the dose administered.  
Heparin clearance occurs through the kidney and it is a combination of slower 
first-order mechanism and a rapid saturable phase through binding to receptors on 
endothelial cells (Glimelius et al., 1978) and macrophages where it is depolymerized. 
Heparin neutralization 
 
Protamine sulfate (PS).  In 1868, protamine was identified by Friedrick 
Miescher as a nitrogenous base bound to nuclear material of Rhine salmon sperm 
heads. In 1937, Chargraff and Olsen demonstrated that protamine sulfate could 
neutralize the anticoagulant action of heparin (Chargaff et al., 1937). Today, 
protamine is usually commercially prepared from salmon milt into a dried powder or 
solution.  It has the ability to reverse the anticoagulant activity of heparin. Protamine 
is arginine-rich (nearly 67%) and strongly basic, Small nuclear proteins (45kDa) 
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replace histones late in the haploid phase of spermatogenesis and are believed to be 
essential for sperm head condensation and DNA stabilization (Zhou et al., 2013). 
Protamine has a mild anticoagulant effect when administered alone. However, 
when it is given in the presence of heparin (which is strongly acidic), ionic forces 
form a stable precipitate. In this stable precipitate an intermolecular charge 
neutralization occurs, thereby causing the neutralization of heparin activity (Adkins et 
al., 1967). Various factors influence the interaction of protamine and heparin 
including individual molecular weight of a given protamine or heparin, charge type, 
and charge density (Moss et al., 1986). Heparin’s affinity for protamine is directly 
influenced by many factors such as molecular weight, degree of sulfation, and 
position of sulfate residues on the heparin chain (Dawes et al., 1982). Dawes and 
Pepper (1982) determined that degree of sulfation is the most important determinant 
of heparin’s affinity to protamine. The binding of protamine to heparin most likely 
dissociates heparin from AT, thereby breaking the heparin/AT complex and 
neutralizing heparin’s anticoagulant activity (Okajima et al., 1981). 
Other agents that have been evaluated for their ability to neutralize UFHs 
including polybrene and PMX60056. Polybrene (hexadimethrine bromide), a 
quaternary ammonium polymeric salt, is a synthetic heparin antagonist used in 
clinical laboratories to neutralize the anticoagulant effects of heparin as well as to 
determine heparin activity in human plasma (Montalescot et al., 1990). PMX 60056 
(PolyMedix Inc., Radnor PA) is the clinical lead compound of a series of small 
molecule oligomers that interact strongly with heparin and LMWHs. 
 
16 
 
 
 
Platelet factor 4 (PF-4).  Platelet factor 4 (PF-4) is a natural antagonist of 
heparin. PF-4 has a mean molecular weight of 7.7 kDa and is 70 amino acids long. It 
is synthesized by megakaryocytes and stored in the alpha granules of platelets (Barber 
et al., 1972). PF-4 is released from platelets by thrombin in the form of a high 
molecular weight PF-4 tetramer, acomplex with two chondroitin sulfate proteoglycan 
molecules (Barber et al., 1972). The moment it is released, it is capable of 
neutralizing the anticoagulant effects of heparin in plasma (Kaser-Glanzmann et al., 
1972). The tetrameric form of PF-4 is essential for the high affinity heparin binding 
(Mayo et al., 1989).  
Similar to the case of heparin’s inhibition of thrombin, a heparin chain length 
greater than 18 saccharides is required for optimal PF-4 binding (Lane et al., 1984). 
Heparin molecules above 18 saccharides with both anti-thrombin and anti-factor Xa 
activities can be completely neutralized by PF-4, whereas molecules below 18 
saccharides, which retain anti-factor Xa activity, are more resistant to neutralization 
by PF-4. A weaker neutralization by PF-4 has been seen for LMWHs in comparison 
to that of heparin (Lane et al., 1984).  
One manifestation of heparin’s interactions with platelet factor 4 is its ability 
to cause heparin induced thrombocytopenia (HIT). HIT is characterized by a severe 
decline in platelet count (>50%) in association with new thromboembolic 
complications (Chong B. H. 2003).  
When PF-4 is released from platelets it binds to heparin, resulting in a 
conformational change in PF-4. This complex is considered a foreign antigen within 
the body and may be immunogenic. The immune response is characterized by initial 
IgM antibody formation, and followed by the development of IgG antibodies on the 
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5th day (Warkentin, 1998). The IgG antibodies form a complex with heparin and PF-4 
in the bloodstream. The tail of the IgG antibody binds to the Fc receptor on the 
surface of platelets leading to their activation. These activated platelets have a 
markedly shortened survival and are acutely consumed in prothrombotic processes, 
resulting in thrombocytopenia. HIT generally occurs 5 to 14 days after initiation of 
heparin therapy (Warkentin, 1998).  
Low molecular weight heparin (LMWH) 
Although UFH is the cornerstone of treatment of various thrombotic diseases, 
including VTE, DVT, and PE, it exhibits some pharmacologic disadvantages. 
LMWHs are an important alternative to UFH with several advantages, such as higher 
bioavailability, enhanced safety (less bleeding), greater convenience (fewer 
injections), and better efficacy (lower rate of thrombotic events). Some of the most 
common commercially available LMWHs are enoxaparin sodium, dalteparin sodium, 
tinzaparin sodium, ardeparin sodium, and second-generation LMWH, bemiparin 
sodium (Dietrich et al., 1999).  
LMWHs are produced by controlled enzymatic or chemical depolymerization 
of UFH either by heparinase, a combination benzylation followed by alkaline 
hydrolysis, nitrous acid degradation, or peroxidative cleavage (Weitz 1997). The 
different methods produce LMWHs with different biochemical and pharmacological 
profiles. Therefore, LMWHs are not interchangeable unless parallel clinical trials 
have been performed for each specific clinical indication (Bick et al., 2005).  
LMWHs consist of short chain polysaccharides, which are approximately one-
third the size of UFH (Fareed et al., 1998). LMWHs are defined as heparin salts 
having at least 60% of all chains with a molecular weight less than 8.0 kDa. On 
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average, LMWHs have molecular weights ranging between 3.5 to 6.5 kDa (Gray et 
al., 2008).  
Because of their lower molecular weight, LMWHs have several distinct 
characteristics from UFH. Firstly, in contrast to UFH, which has an anti-FXa/anti-FIIa 
ratio equal to 1, LMWHs have a ratio which is greater than 1.  This ratio generally 
increases as the molecular weight of the compound decreases (Gray et al., 2008). A 
greater anti-FXa/anti-FIIa ratio denotes a reduction in bleeding, which is often a side 
effect of UFH. Secondly, having smaller molecular weight components means 
LMWHs are better absorbed following subcutaneous administration. While UFH has 
a bioavailability of approximately 20 to 30 percent (Fareed, 1985), LMWHs are 
virtually 100 percent bioavailable after subcutaneous injection (Weitz, 1997). 
Moreover, the plasma half-life of LMWHs is two to four times longer than that of 
UFH; however, this is dependent on the dose, route of administration, and assay used 
to detect the anticoagulant activity (Fareed et al., 1985). LMWHs are a more 
predictable anticoagulant because they have a decreased propensity to bind to plasma 
proteins, macrophages, and endothelial cells in comparison to UFH. Consequently, 
LMWHs are less likely to cause heparin-induced thrombocytopenia (HIT) (Baroletti 
et al., 2008), can be administered once daily, and do not require continuous 
monitoring. 
Currently, various generic versions of LMWH are available in the market. 
Compared to their branded counterparts, these agents are cheaper. Many works of 
literature have shown that generic LMWHs not only exhibited similar structural 
composition but also exhibited comparable anticoagulant and antiprotease activities 
when compared to their branded counterparts (Maddineni et al., 2006).  
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 (ULMWHs) have been developed as a response to trying to produce safer and 
more efficacious heparin and LWMHs. ULMWHs are obtained by a selective and 
controlled depolymerization of heparin and have mean molecular weights ranging 
between 2-3 kDa. ULMWHs mainly act through the inhibition of the coagulation 
enzyme factor Xa and, to a lesser extent, factor IIa (thrombin). 
Animal-sourced low–molecular weight heparins are widely used to treat 
various clotting disorder. Because it is poorly controlled, and its anticoagulant activity 
is not fully reversible by protamine, a synthetic homogeneous oligosaccharide can be 
used as a replacement. Dodecasaccharide is a synthetic homogeneous oligosaccharide 
with MW of 3.5 (kDa). It has high affinity to antithrombin and exhibits anti-Xa 
activity along with very weak anti-IIa actions which are comparable to LMWHs. In 
vitro and ex vivo experiments have shown that the anticoagulant activity of 
dodecasaccharide can be reversed by protamine. (Xu et al., 2017). 
Bioheparins 
 Currently, the heparin used both in the manufacturing of LMWHs and 
clinically reply upon livestock animal tissues. The variability of animal-sourced 
heparin and heparin sulfates their inherent impurities, the limited availability of 
source tissues, and the poor control of these source materials and their manufacturing 
processes, all suggest a need for new approaches to their production. Over the past 
decade, there have been major efforts in the biotechnological production of 
glycosaminoglycans, such as mitrin from plants and bacteria. Mitrin is a chemically 
engineered anticoagulant polysaccharide prepared from Escherichia coli K5 
polysaccharide to replace heparin (Kuberan et al., 2003). Casu and coworkers 
described the generation of a series of heparin-like products through regioselective 
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sulfation of the capsular polysaccharide from Escherichia Coli K5 (Casu et al., 1994). 
The capsular polysaccharide from E. coli has the same basic structure as heparin 
[→4)-β-D-GlcA-(1→4)-α-D-GlcNAc-1(1→]. 
The polymeric backbone known as N-acetyl heparosan provides a novel 
starting material to develop semi-synthetic heparin-like molecules. To accomplish 
this, the bacterial polysaccharide is first converted to sulfaminoheparosan by 
deacetylation (through hydrazinolysis) followed by N-sulfation. Controlled O-
sulfation of this product results in the generation of a series of novel heparin-like 
oligosaccharide mixtures with varying O-sulfation patterns and anticoagulant 
activities. This sulfated oligosaccharide also shows varying degrees of binding to AT 
due to the presence of 3-O- sulfated glucosamine unit. Thus, utilizing these semi-
synthetic approaches, anticoagulants with structural identities distinct from heparin, 
yet with similar interactions with HC-II and AT, can be developed.  These bacterial 
polysaccharide derivatives interact with AT and promote its anticoagulant action in a 
manner similar to that of heparin (Razi et al., 1995). Depending on the reaction 
conditions during their preparation, the products showed different proportions of 
components with high affinity for AT. A high affinity fraction of this bacterial 
polysaccharide was shown to cause conformational changes in the AT molecule very 
similar to those induced by high-affinity heparin. The compositional analysis of these 
polysaccharide fractions revealed that they have the AT binding site, the 3-O sulfated 
GlcN unit, which has previously been identified as the marker component of the AT 
binding pentasaccharide sequence in heparin. Due to the charge density of these 
agents, they may also share other biological activities with heparin including 
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endogenous release of mediators such as TFPI, modulation of adhesion molecules, 
interaction with endothelial cells and anti-inflammatory effects.  
      Therefore, a substitute for both UFH and LMWHs may be semisynthetic heparin-
like anticoagulants. Furthermore, semisynthetic heparin-like anticoagulants can be 
structurally modified by chemical or enzymatic methods to achieve drugs with 
desirable biochemical and pharmacological profile. It is expected that these agents 
will exhibit all the biological actions that are associated with heparins (Fu, L. et al., 
2016). 
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CHAPTER TWO 
STATEMENT OF PURPOSE 
Unfractionated heparin (UFH) is one of the oldest drugs that is still in clinical use. 
UFH is the most widely used anticoagulant drug for the surgical and interventional 
indications. Unfractionated heparin and low molecular weight heparin (LMWHs) are 
widely used for the management of thrombotic and cardiovascular disorders. Most of the 
heparins are derived from pig mucosa (porcine mucosa). However, heparin has also been 
manufactured from other mammalian sources such as bovine (cow) and ovine (sheep). 
Although most of the heparins used globally are obtained of porcine origin, bovine and 
ovine heparins have also been used in non-Western markets. The North American and 
European community primarily use heparins derived from porcine sources, which are 
primarily of Chinese origin. Worldwide there are 1.4 billion cattle, 1.9 billion sheep and 
goats and 980 million pigs. Both cow and sheep provide alternate sources of heparin 
which are not widely used due to regulatory reasons. Currently there are some concerns 
about the shortage of the porcine heparins as they are widely used in the manufacturing 
of the low molecular weight heparins (LMWHs). Also, open-heart surgeries, 
hemodialysis and intervention cardiovascular procedures are usually carried out with 
anticoagulants and unfractionated heparins. Moreover, due to cultural and religious 
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reasons in some countries, alternative sources of heparins are needed. The FDA is 
currently considering the introduction of bovine and ovine unfractionated heparins. 
With the advances in technology and manufacturing processes, higher quality 
bovine and ovine heparins are now available. In addition, the biologic contaminants such 
as bovine spongiform encephalopathy (BSE) are eliminated. Currently bovine and ovine 
heparins are used in various part of the world and have been shown to exhibit similar 
biologic and clinical profiles. Several Brazilian and Chinese manufacturers provide 
bovine and ovine heparins for clinical use.  
UFHs produce their effects via interactions with various endogenous proteins 
such as antithrombin (AT) and heparin cofactor II (HCII). UFHs mechanism of action 
relies in large part to specific pentasaccharide sequence that enables binding to 
antithrombin. This binding results in a conformational change in antithrombin that 
facilitates inactivation of thrombin (Factor IIa) and Factor Xa, leading to a significant 
increase in anticoagulant activity. The degree to which these compounds exert their 
effects through AT and HCII, as well as other endogenous proteins, determines how well 
they inhibit various targets of the coagulation system and the severity of side effects.  
The primary purpose of this dissertation was to determine the extent of 
biosimilarity between BMH, OMH and PMH. For this investigation, ten batches of each 
heparin source were utilized. Their activities in biochemical and biological assays were 
compared in order to elucidate how their molecular composition and structural attributes 
affect their pharmacological actions. 
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Ten batches of PMH obtained from Medefil Inc., USA, were used throughout this 
dissertation. The average molecular weight of these batches was 18.5 kDa. Ten batches of 
BMH obtained from KinMaster Pharmaceutical, Brazil, were selected for this study. The 
average molecular weight of these batches was 21 kDa. Ten batches of OMH obtained 
from Ronnsi Pharmaceutical, China, were used throughout this dissertation. The average 
molecular weight of these batches was 17 kDa. All agents were stored in a desiccator at 
room temperature (20 – 25 ºC).  
 This dissertation is focused on delineating the pharmacological actions of various 
heparins by understanding their molecular composition and structural attributes. To 
investigate these claims, the following three specific aims were addressed: 
Specific Aim 1: 
• To compare the molecular weight and structural profiles of bovine, 
ovine and porcine mucosal heparins. 
Specific Aim 2: 
• To compare the functionality of bovine, ovine and porcine mucosal 
heparins in terms of their USP potency, global anti-coagulant and 
anti-protease activities. 
Specific Aim 3: 
• To compare the pharmacodynamics profile of bovine, ovine and 
porcine mucosal heparins following I.V. administration to non-human 
primates. 
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Significance 
Although heparin has provided a universal anticoagulant option with wide spread 
usage as a surgical anticoagulant, it has some other pharmacological properties which are 
not fully understood. Initial supply of heparins was primarily obtained from mammalian 
tissue and source verification was not required. The currently used heparin is mainly 
obtained from porcine mucosa. Heparins from other sources such as bovine lung, bovine 
mucosa, or sheep mucosa are not available for clinical use in the USA. Heparins from 
these sources are available in pharmaceutical quantities and such preparations are 
available in Asian and African countries. Given the number of cattle and sheep, large 
quantities of heparins can be obtained. This thesis provides a comprehensive account of 
the structural and biological actions of heparins obtained from bovine, ovine and porcine 
sources. It also demonstrates the biosimilarity between these heparins and an approach to 
equate their potency in valid functional assays which can potentially deem them 
interchangeable. This study has demonstrated that, despite microchemical differences in 
the degree of sulfation and other compositional variables, heparins obtained from porcine 
and ovine sources are almost identical. The AT binding regions, which facilitates the 
interaction between heparin and antithrombin, are comparable in porcine and ovine 
mucosal heparins. However, BMH shows considerably lower AT affinity. Despite this, 
the potency of BMH can be adjusted to exhibit comparable biological effects to OMH 
and PMH. This dissertation provides a stepwise approach to compare heparins from 
different animal sources and to adjust their potencies utilizing the USP reference or a 
comparable reference heparin.  
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CHAPTER THREE 
 
MATERIALS AND METHODS 
 
Materials 
 
Anticoagulants  
 Porcine mucosal heparin (PMH). Ten samples of porcine mucosal heparin  
 
obtained from Medefil Inc., USA, were used throughout this dissertation. These agents  
 
were stored in a desiccator at room temperature (20 – 25 ºC).  
 
 Bovine mucosal heparin (BMH). Ten samples of bovine mucosal heparin 
obtained from KinMaster Pharmaceutical, Brazil, were used throughout this dissertation. 
These agents were stored in a desiccator at room temperature (20 – 25 ºC). 
Ovine mucosal heparin (OMH). Ten samples of ovine mucosal heparin obtained 
from Ronnsi Pharmaceutical, China, were used throughout this dissertation. These agents 
were stored in a desiccator at room temperature (20 – 25 ºC).   
The average molecular weight (Mw) of PMH, BMH and OMH batches were 18.5 
kDa, 21 kDa and 17.5 kDa respectively as determined by high-performance liquid 
chromatography (HPLC).  
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Protein/Enzymes 
 Heparinase I.  Heparinase I (EC 4.2.2.7) was obtained from IBEX 
Pharmaceuticals, Montreal, Canada. This enzyme was purified from Flavobacterium 
heparinum. Its molecular weight was reported to be 42.5 kDa. The potency was 
designated as >80 IU/mg, where one international unit (IU) is defined as the amount of 
enzyme that will liberate 1.0 mole of unsaturated oligosaccharides from porcine 
mucosal heparin per minute at 30 ºC and pH 7.0 (Ernst et al., 1995). Purity of this 
enzyme was determined to be greater than 90% by reverse-phase HPLC and SDS-PAGE 
analysis. The material was provided as a solution and was stored at –70 ºC until use. 
 Protamine sulfate. Protamine sulfate was obtained from Choay Institute (Paris, 
France) in powder form and reconstituted in normal physiologic saline at a concentration 
of 100 µg/ml. It was produced from salmon sperm and had a specific activity of 138 
UAH/mg. The mean molecular weight of this protamine as determined by HPLC was 4.0 
kDa. 
     Antithrombin. Human antithrombin (AT) was obtained from Sekisui Diagnostics 
(Stamford, CT) in vials containing 2.5 IU. The antithrombin was immunoaffinity purified 
from pooled fresh frozen plasma by heparin-Sepharose chromatography and salt-gradient 
elution. The product was stored at 4 ºC until it was reconstituted with 1 ml of saline. 
Molecular weight profiling 
 The mobile phase used in all the HPLC studies was made using anhydrous 
sodium sulfate (0.3 M Na2SO4, pH = 5.0) and HPLC-grade water from Sigma-Aldrich 
Inc. (St. Louis, MO). Thirteen standard heparin fractions (Sanofi, Paris, France) ranging 
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in molecular weight from 51.0 kDa to 2.4 kDa were used to calibrate the GPC-HPLC 
instrument and to make the standard curve. 
Chromogenic antiprotease BioMed kits 
  Heparin anti-Xa and anti-IIa USP kits were obtained from HYPHEN Biomed, 
France. The anti-Xa and anti-IIa USP kits numbers were 221010 and 221025 
respectively.  These are chromogenic assays developed to measure heparins 
concentrations in plasma or in purified solutions in terms of their anti-Xa and anti-IIa 
activities.  
Blood products 
 Blood bank plasma (BBP). Normal human CPDA-1 (citrate phosphate dextrose 
adenine) plasma was obtained from the Blood Bank, Department of Pathology, Loyola 
University Medical Center, Maywood, IL. This plasma was obtained from blood donated 
by normal healthy human volunteers who tested negative for acquired immunodeficiency 
syndrome (AIDS) and hepatitis B and C viruses. The fresh frozen plasma packs (n = 5), 
not more than 30 days old, were thawed at 37 ºC, and then the pooled plasma was 
aliquoted in volumes of 10 ml and refrozen at –70oC for a period of not more than two 
months. 
Normal monkey plasma (NMP). Primates (Macaca mulatta) were anesthetized 
with ketamine (10 mg/kg, I.M.) and blood samples were drawn from the saphenous vein 
using a 21-gauge ¾ inch butterfly needle and a 5 ml syringe. The blood was transferred 
into a 4.5 ml sodium citrate (3.2%) BD Vacutainer® blood collection tube (Becton 
Dickinson and Company, Franklin Lakes, NJ). Approximately 15 minutes later, the blood 
was centrifuged at 4°C, 3,000 rpm (2,053 x g) for 20 minutes. Plasma from a minimum 
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of 14 primates was pooled and aliquoted in 10 ml volumes. The pooled monkey plasma 
(NMP) was frozen in plastic tubes at -70°C for not more than 2 months. 
Major instruments 
Major instruments used to perform various experiments reported in this 
dissertation include a WatersTM high-performance liquid chromatography (HPLC) system 
(Milford, MA). This was used to determine the molecular profile of the various 
compounds. Nuclear Magnetic Resonance (NMR) spectroscopy was performed using a 
Bruker 400 MHz and 600 MHz AVANCE III NMR spectrometer (Bruker, Germany). An 
ACLTM Elite (Beckman-Coulter, Miami, FL) was used for antiprotease assays. A 
SpectraMax® Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, 
CA) was used to measure clot lysis, kinetics of various assays, and with the ELISA 
method. PAP-8E from Bio/Data Corporation was used to measure the rate and extent of 
platelet aggregation reactions.  
Non-human primates 
 Male and female non-human primates (Macaca mulatta) (4 - 16 kg) were used for 
the studies on the pharmacologic actions of heparins. The non-human primates are part of 
a colony currently housed at the Loyola University Chicago Health Sciences Division 
according to the institutional IACUC protocols of Loyola University Medical Center. All 
experiments were non-terminal and approved by the Loyola University Chicago Health 
Sciences Division IACUC (LU # 208582 (0.02); P/D # 032-16; IACUC # 16-040). The 
primates were anesthetized using ketamine HCl (100 mg/ml) obtained from Webster 
Veterinary (Devens, MA). Hematologic profiles and serum chemistry profiles were 
performed at the Clinical Laboratory, Department of Pathology at Loyola University 
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Medical Center using a Beckman Coulter LH 750 Hematology Analyzer (Beckman 
Coulter Inc, Indianapolis, IN). 
 All animal studies were carried out in compliance with the guidelines set forth by 
the Institutional Animal Care and Use Committee (IACUC), Loyola University Medical 
Center and the Principles of Laboratory Animal Care (National Institutes of Health, 
1985). 
Methods 
Physiochemical characterization of agents 
Gel permeation chromatography. Molecular weight determinations were made 
using GPC in a high-performance liquid chromatography (HPLC) system (Waters 845, 
Millipore-Waters, Lexington, MA) equipped with Millennium 2000 software designed 
for polymer analysis. The HPLC system consists of a computer, a LAC/E interface 
module, two 510 HPLC pumps, a 712 WISP auto-injector, a 2404 differential refraction 
index (RI) detector, and a 2487 ultraviolet (UV) tunable absorbance detector. The UV 
and the RI detectors were linked in series, with the outlet of the joint columns (TSK 
G3000SW and TSK G2000SW, TosoHaas, Tokyo, Japan) attached to the UV detector. 
The molecular weight profile of each agent was determined using the method 
reported by Ahsan et al. (1995). The system was equilibrated using freshly degassed 
mobile phase (0.3 M sodium sulfate) until a stable baseline was obtained. Analysis was 
carried out by injecting 20 μl of sample (10 mg/ml in 0.3 M sodium sulfate) into the 
HPLC system. The flow rate for the mobile phase was 0.5 ml/min and the run time for 
each sample was 65 minutes. The internal temperature for the RI detector was set at 35C 
and UV detection was made at 205 nm.  
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Following each run, the elution profile of each sample was analyzed by the 
narrow range calibration (NRC) method (Ahsan et al, 1995; Ahsan et al, 1993). The NRC 
method uses 13 calibrators ranging from 51.0 kDa to 2.4 kDa and requires the UV 
detector to be set at a wavelength of 205 nm.  
Calibration of the HPLC system was performed in a similar manner using the 
narrow range calibrators (10 mg/ml calibrators in 0.3 M sodium sulfate) with well-
defined molecular weights. The log molecular weight of each calibrator was plotted 
against its retention time. Using the Millennium 2000 software, a third order polynomial 
regression equation (Log MW = D0 + D1 (RT) + D2 (RT)
 2 + D3 (RT)
 3) was fitted to the 
data points, where MW represents the calculated molecular weight, RT represents 
retention time and D0, D1, D2 and D3 represent coefficients calculated in the curve fitting 
process. The molecular weight profile of each agent was determined based on this 
calibration curve. The molecular weight profile consists of such parameters as weight 
average molecular weight, number average molecular weight, and polydispersity. 
 Nuclear magnetic resonance spectroscopy. Nuclear magnetic resonance (NMR) 
spectroscopy was performed using a Bruker 400 MHz and 600 MHz AVANCE III NMR 
spectrometer (Bruker, Germany) with a 5-mm inverse Z gradient probe. BMH, OMH, 
and PMH pools were investigated. Deuterated water of 99.8% purity containing 0.1% 
trimethylsilyl propanoic acid (TSP) as internal standard was purchased from Euriso-top 
(Saarbrücken, Germany). Cs2CO3 (99.5%) was provided by Sigma Aldrich (Steinheim, 
Germany). EDTA was obtained from AppliChem (Munich, Deutschland).  
             NMR measurements were performed on Bruker Avance III 600 MHz 
spectrometer (Bruker Biospin, Rheinstetten, Germany) with BBO cryo probe equipped 
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with Bruker Automatic Sample Changer (B-ACS 120) at 297 K. NMR spectra were 
recorded with standard pulse program (zg30 in Bruker language) using 16 scans and 2 
prior dummy scans (Monakhova, Y. B. et al., 2015). The data of 132k points were 
acquired with a spectral width of 24.0155 ppm, a receiver gain of 72, an acquisition time 
of 4.5438 s. The data were recorded automatically under the control of ICON-NMR 
(Bruker Biospin, Rheinstetten, Germany). All NMR spectra were manually phased and 
baseline-corrected using Topspin 3.2 (Bruker Biospin, Rheinstetten, Germany). 
Global anticoagulant assays 
 Activated partial thromboplastin time (aPTT). The activated partial 
thromboplastin time is a screening test for the intrinsic pathway of coagulation (factors I, 
II, V, VIII, IX, X, XI and XII) and is commonly used for monitoring heparin therapy. It is 
based on the measurement of time to clot after plasma has been activated by a platelet 
substitute (purified phospholipids) plus added activator (micronized silica) and calcium 
chloride.  
 The TriniCLOTTM APTT S kit (Trinity Biotech USA Inc, Jamestown, NY) was 
used to determine the APTT of the test samples. The following reagents were included in 
the TriniCLOTTM APTT S kit: TriniCLOT APTT CaCl2 (0.02 M) and TriniClOT APTT 
S reagent. The reagent contains purified phospholipids (porcine and galline), micronized 
silica (activator), stabilizer, and 0.02% sodium azide as preservative. All reagents were 
kept refrigerated (4C) until use. Each vile of TriniCLOT APTT CaCl2 (0.02 M) and 
TriniClOT APTT S reagent came ready to use. 
When the assay was utilized for human or primate plasma, the assay was 
performed as follows. An aliquot of 250 µl of each of the plasma samples were placed 
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into individual test cups, which are then placed in an ACL test cup carousel in a defined 
sequence. NHP or NMP and saline samples were included in every carousel as controls. 
The reagents were placed in their appropriate positions (TriniCLOT APTT S reagent in 
position 2 and CaCl2 in position 3). A clean ACL rotor was placed in the carousel. The 
appropriate parameters were set on the machine before running the test. An aliquot of 100 
µl of each of the plasma samples and 100µl of APTT reagent were incubated at 37°C for 
5 minutes. After 5 minutes of incubation, prewarmed calcium chloride was added to 
trigger coagulation and the clotting times were then measured on an ACL Elite 
(Beckman-Coulter, Miami, FL). Measurement of clotting time was stopped at 300 
seconds as clotting times beyond 300 seconds are outside of the linear range of the 
instrument.  
Thrombin time (TT). Thrombin time (TT) is a clot-based assay, which measures 
the time it takes for thrombin to convert fibrinogen to fibrin after the addition of a known 
amount of thrombin to plasma. Thrombin was obtained from Enzyme Research 
Laboratories (South Bend, IN) and was reconstituted with 0.02 M CaCl2 to yield 5 U/ml 
solution which gave a baseline clotting time of 9±1.8 seconds. Thrombin was kept frozen 
at -70°C until use. The assay was performed as follows. 200 l of test plasma, calibration 
curve or control was added to a test cup and incubated at 37 ºC. After three minutes, 100 
l of 5 U/ml thrombin was added, and the clotting time was measured using ACL Elite. 
Chromogenic antiprotease assays 
Anti-factor Xa assay. The inhibition of factor Xa in human and primate samples 
was performed on the ACL Elite fast kinetics coagulation analyzer (Beckman-Coulter, 
Hialeah, FL), in the following manner. Test samples were prepared by placing 250 l of 
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test plasma into individual test cups, which were then placed in an ACL-test cup-carousel 
and their positions were recorded. Up to 40 plasma samples could be inserted into one 
carousel. Normal human pool plasma and saline samples were included in every carousel 
as controls. Bovine factor Xa (1.0 mg/ml) (Enzyme Research Laboratories, South Bend, 
IN) was reconstituted with 4 ml (final factor Xa concentration of 6µg/ml) of Xa/IIa buffer 
(50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800 mls distilled H2O, pH = 8.4, 25 
ºC) prior to use. The substrate, Spectrozyme FXa (5 µM) (Sekisui Diagnostics, Stamford, 
CT) was reconstituted by adding 2 ml of distilled water. The reagents were placed in their 
appropriate positions (bovine factor Xa in position 2 and Spectrozyme FXa in position 3). 
A clean ACL rotor was also placed in the instrument. Once the reagents and samples 
were in their proper places, the ACL keypad was used to set the appropriate 
specifications for the anti-Xa assay. An aliquot of 10 l of plasma was incubated for 1 
minute at 37 ºC, followed by the addition of 100 l of bovine factor Xa. After five 
minutes incubation at 37 ºC, 75 l of Spectrozyme FXa was added and the optical density 
change at 405 nm was measured for 30 seconds. 
The results were processed on an IBM compatible PC. The results were given as 
optical density (O.D.) values which were converted to % factor Xa inhibition using the 
following equation:  % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100] 
Anti-factor IIa assay.  The inhibition of factor IIa in human and primate plasma 
samples was measured on the ACL Elite fast kinetics coagulation analyzer (Beckman-
Coulter, Hialeah, FL), in the following manner. Test samples were prepared by placing 
250 l of test plasma into individual test cups, which were then placed in an ACL test 
cup carousel and their positions were recorded. Up to 40 plasma samples could be loaded 
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into one carousel. Normal human or primate pool plasma and saline samples were 
included in every carousel as controls. Human thrombin (Enzyme Research Laboratories, 
South Bend, IN) was diluted to 5 U/ml in Xa/IIa buffer. The substrate, Spectrozyme TH 
(Sekisui Diagnostics, Stamford, CT) was reconstituted by adding 5 ml of distilled water 
(5 µM). The reagents were plated in their appropriate positions (thrombin in position 2 
and Spectrozyme TH in position 3). A clean ACL rotor was also placed in the instrument. 
Once the reagents and samples were in their proper places the ACL keypad was used to 
set up the appropriate specifications for the anti-II assay. A 10 l aliquot of plasma was 
incubated for 1 minute at 37 ºC, followed by the addition of 100 l of thrombin. 
Following one-minute incubation at 37 ºC, 40 l of Spectrozyme TH was added, and the 
optical density change at 405 nm was measured for 30 seconds. 
The results were processed on an IBM compatible PC. The results were given as 
optical density (O.D.) values which were converted to % factor IIa inhibition by using the 
following equation:  % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100] 
Chromogenic antiprotease assays (BioMed kits) 
 The USP potency was determined accordance to the specifications and directions 
provided by the manufacturers (HYPHEN BioMed). Commercially available kits were 
utilized. The anti-Xa and anti-IIa kits numbers were 221010 and 221025 respectively. 
Heparin anti-Xa and anti- IIa assays are two-step chromogenic methods based on the 
inhibition of a constant amount of factor Xa or factor IIa by the tested heparin in the 
presence of exogenous AT (stage 1). Then any excess factor Xa or factor IIa hydrolyzes a 
factor Xa specific chromogenic substrate or a factor IIa specific chromogenic substrate, 
respectively (stage 2). There is an inverse relationship between the concentration of 
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heparin and color development, measured at 405 nm using a SpectraMax® Plus384 
Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA). Dilutions of the 
drugs were prepared using AT-supplemented buffer at concentrations ranging from [0 – 
10 µg/mL]. All results were plotted in terms of concentration effect curves.  
AT supplemented system assay 
A standard method used in the Hemostasis and Thrombosis Research Lab was 
employed to determine the anti-Xa and anti-IIa activities in an AT supplemented system. 
Here 250 µL of AT supplemented buffer containing varying concentrations of each of the 
individual heparins in the range of 0-10 µg/mL was mixed with a known amount of 
thrombin or factor Xa. The relative inhibition of these enzymes was measured using a 
kinetic analyzer, monitoring the amidolysis of either Xa or IIa substrate. The IC50 was 
calculated as the amount of heparin which produced 50% of the inhibition of the 
enzymatic activity. The, anti-Xa and anti-IIa assays were performed on the ACL Elite 
machine. 
Heparinase-I digestion studies 
Heparin pools were subjected to heparinase digestion in the following manner: An 
aliquot of 70 µl of each agent (10 mg/ml) was added to an eppendorf tube along with 10 
µl of CaCl2, 10 µl of either heparinase (10 U) or saline (vehicle control), and an 
additional 10 µl of saline for a total volume of 100 µl. The solutions were mixed, 
incubated for 30 minutes at 37°C, and then placed in a 100°C hot water bath for 3 
minutes. The final heparinase concentration was 1.0 U. After digestion, the 
heparinase/agent or saline/agent solutions were supplemented in normal human plasma to 
obtain final concentrations ranging from 0 - 10 μg/ml. Anticoagulant activity was 
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determined prior to and after the digestion using the APTT and thrombin time assays. 
Antiprotease activity was determined prior to and after the digestion using anti-Xa and 
anti-IIa assays. The molecular profile was determined prior to and after the digestion of 
each pool using GPC in a high-performance liquid chromatography (HPLC) system. 
Protamine sulfate neutralization studies 
Heparin pools were supplemented in blood bank plasma to obtain final 
concentrations ranging from 0 - 10 μg/ml. Protamine sulfate was added to the heparin 
supplemented plasma to obtain a final protamine concentration of 10 μg/ml. 
Anticoagulant activity was determined using the APTT and the thrombin time assays. 
Antiprotease activity was determined using anti-Xa and anti-IIa assays.  
Heparin induced thrombocytopenia (HIT) screening 
The heparin derivatives were evaluated for their ability to promote platelet 
aggregation induced by HIT antibodies according to the method of Brace (Brace et al., 
1990). Whole blood was drawn from healthy volunteers (n=10) using a double syringe 
technique to avoid contamination by tissue factors released upon venipuncture (IRB # 
9191051098). Standard venipuncture was performed using Vacutainer brand Safety-
LokTM blood collection sets (23 G ¾, 0.6  19mm, Becton Dickinson and Company, 
Franklin Lakes, NJ). Nine mls of blood was transferred to plastic test tubes containing 1 
ml of 3.2% sodium citrate. Platelet rich plasma (PRP) was prepared by centrifuging the 
citrated blood at 800 rpm (146 x g) for 15 minutes at room temperature. After removing 
PRP, the remaining blood was spun further at 3,000 rpm (2,053 x g) for 15 minutes to 
obtain platelet poor plasma (PPP). PPP was used to blank the aggregometer (PAP-8) 
(BioData Corporation, Horsham, PA). Aggregations were performed in the following 
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manner. Aliquots of 290 µl of PRP and 160 µl of HIT serum were warmed in a cuvette 
for 1 to 2 minutes at 37oC. 5, 10, or 20 µl of a 1 mg/ml solution of each heparin being 
tested was then added. The platelet aggregation response was monitored for 30 minutes.          
Heat inactivated pooled HIT apheresis fluid was used as a source of HIT antibodies and   
was obtained from patients (3-5) clinically diagnosed with heparin-induced 
thrombocytopenia. The functionality of these antibodies was verified by using platelets 
aggregation assays in the presence of heparins and by performing the quantitation of 
these antibodies using a commercial available assay (GTI - PF4 ENHANCED® Solid Phase 
ELISA) for the detection of PF4 heparin-dependent antibodies (GTI Diagnostics, 
Waukesha, WI).  
In Vivo studies in non-human primates 
     Comparative pharmacodynamics investigation of various heparin pools. 
Twelve male and female Rhesus monkeys (Macaca mulatta) weighing 4.0 – 16.0 kg were 
used for pharmacodynamics studies. The animals were animal housed in individual cages 
in accordance with the Guide for the Care and Use of Laboratory Animals and the 
National Research Council. All research was conducted in compliance with the 
guidelines set forth by the Institutional Animal Care and Use Committee (IACUC), 
Loyola University Medical Center and the Principles of Laboratory Animal Care. 
The three heparin pools used in this study were BMH, OMH, and PMH. Each 
agent was dissolved in 0.9% physiologic saline prior to administration to groups of 
primates (n=12). Squeeze cages were used to anesthetize the primates with an 
intramuscular injection of ketamine (10 mg/kg) + xylazine (1-2 mg/kg) based on the most 
recent charted weight. The primates were weighed regularly on- and off-study and a 
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record of these weights is kept in the animal room. Following attainment of anesthesia, 
primates were removed from their cages and carried to the procedure room where they 
were freshly weighed to accurately determine the dose of the test agent. The skin over the 
saphenous vein was shaved as necessary and then cleaned using betadine and alcohol. A 
baseline blood sample was collected by venipuncture of the saphenous vein. Test agent 
was administered at a dose of 0.5 mg/kg intravenously via the saphenous vein. Additional 
blood samples were collected at 15, 30, 60 and 120 minutes post-drug administration. 
After administration of the test agent and after collection of each of the subsequent blood 
samples, primates were returned to their cages and monitored continuously until they had 
awakened from anesthesia and were able to sit up on their own. 10-15 minutes prior to 
each blood draw, the sedation state of the animal was assessed. Additional doses of 
ketamine were given intramuscularly as needed.  
All blood samples were drawn using a double syringe technique, employing a 21-
gauge butterfly needle. After an initial ~1 ml volume (discard blood) was collected, the 
syringe was changed, and a 2.7 ml sample was drawn and placed into a tube containing 
0.3 ml 3.2% sodium citrate. The discard blood from the baseline samples were placed in 
an EDTA tube and used to measure the complete blood count (CBC) of the primate. 
Results of the CBC were recorded in the primate health record and reported to CMF. 
Citrated blood samples were centrifuged, and aliquots of plasma were stored for 
analysis of circulating drug levels and tissue factor pathway inhibitor levels. Circulating 
concentrations of the drugs were calculated based on calibration curves constructed by 
supplementing NHP with BMH, OMH, and PMH over a concentration range of 0 - 10 
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μg/ml.  Area under the curve values were calculated for each parameter and compared to 
determine whether the heparins derived from different sources were bioequivalent. 
 Comparative pharmacokinetics investigation of various heparin pools. 
Concentration-response curves were made by supplementing various heparin pools in 
pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml. Plasma 
concentrations of various heparin pools were plotted against corresponding sample times 
using graphing software, GraphPad Prism® Version 7.0 for Windows (GraphPad 
Software, San Diego, CA). Best-fit curves were made and the drug concentration in each 
primate blood sample was determined by extrapolation using the measured percent 
inhibition of factor Xa and thrombin. The extrapolated plasma concentrations were used 
to calculate values for the pharmacokinetic parameters such as elimination half-life 
(T1/2), area under the plasma concentration time curve (AUC), systemic clearance (Cl) 
and volume of distribution (Vd). Pharmacokinetic (PK) parameters were calculated by 
non-compartmental analysis using PKSolver® software. 
Data Processing and Statistical Analysis 
The experimental data obtained in this dissertation is presented as the mean ± 
standard deviation (SD) or mean ± standard error of the mean (SEM) and is indicated as 
such throughout this document. The results obtained from the biochemical experiments 
were analyzed using a two-way analysis of variance (ANOVA) followed by a Bonferroni 
multiple comparison test. This analysis was used to determine statistically significant 
differences between the effects of various heparins. Potency comparisons (IC50) were 
compared using a one-way ANOVA followed by a Tukey multiple comparison test. 
Other data were analyzed using one of the following statistical tests as such: Students t-
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test (unpaired), one-way ANOVA with a Tukey multiple comparison test, Pearson’s chi-
square test and Fisher’s exact test. In all cases a p value < 0.05 was considered 
statistically significant. Computed p values were presented for each analysis. Graphs with 
data and error bars were drawn using Microsoft Excel (Microsoft ® Corporation, 
Redmond, WA) or GraphPad Prism for Windows (GraphPad Software, San Diego, CA). 
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CHAPTER FOUR 
RESULTS 
Physicochemical characterization of various heparins 
 The structural, compositional, and molecular characteristics of heparin and its 
derivatives play an important role in the determination of their biological properties. 
Therefore, molecular weight distribution, heparinase-I digestion profile and nuclear 
magnetic resonance (NMR) analyses were performed on all agents to characterize their 
physicochemical properties. These results are described in the following sections 1 and 2. 
Gel-permeation chromatography 
Molecular weight profiles. The molecular weight profiles for bovine, ovine and 
porcine heparins were determined by gel-permeation chromatography (GPC) in a high-
performance liquid chromatography (HPLC) system. The molecular weight of each 
sample was determined by a narrow range calibration (NRC) method as previously 
described in the ‘Materials and Methods’ section. The elution profiles for bovine, ovine 
and porcine heparin pools which were analyzed using the NRC method, are shown in 
Figure 4. 
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A.      UV Profile 
 
 
B.    RI Profile 
 
Figure 4.  Elution profiles of bovine (black), ovine (blue) and porcine (green) pools as 
measured by gel permeation chromatography (GPC) using the NRC method.  Both the 
UV 205 nm (A) and RI (B) detector methods were used.  Panel A, shows the UV profile 
whereas the panel B, shows the RI profile. 
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The elution profiles using the UV detection method are shown in panel A, while 
Panel B shows the elution profiles using the RI detection method. The calculated 
molecular weights were comparable between the UV and RI detectors. 
The elution time for each sample is defined as the time between the start of 
separation (the time at which the solute enters the column or the beginning of the peak) 
and the time at which the sample fully elutes (end of the peak). OMH and BMH showed 
the broadest peaks, with elution times of approximately 19 and 20 minutes respectively, 
indicating higher degree of heterogeneity compared to the PMH. PMH had elution time 
which spanned approximately 16 minutes, which relatively a narrow peak indicating that 
it has a higher degree of homogeneity compared to the other agents. The trends were 
similar between the UV and RI profiles. 
            The molecular weight profiles for various batches of PMH, OMH and BMH 
obtained with the UV and RI detectors for the NRC method are tabulated in Table 1, 2 & 
3. Since heparins are heterogeneous in nature, the molecular weights of the various 
heparins determined by GPC represent average molecular weights cross referenced to the 
NRC curves. 
          As seen in Table 4, BMH pool exhibited the highest mean of weight average 
molecular weight (Mw) of 21974 (±387) Da as measured by UV detection when using 
the NRC method. The PMH and OMH exhibited slightly lower means of weight average 
molecular weight (Mw) of 18601 (±534) Da and 18187 (±265) Da, respectively. The 
weight average molecular weight (Mw) of the various heparin batches exhibited the same 
rank order as shown in Tables 1, 2 and 3. The values of weight average molecular weight 
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(Mw) of all heparins obtained by RI detector were comparable to the UV detector ones 
with the same the rank order. 
As seen in Table 4, BMH pool had slightly higher polydispersity of 1.35 (±0.07) as 
measured by UV detection compared to all other pools when determined by the NRC 
method. PMH and OMH pools had comparable polydispersity of 1.26 (±0.08) and 1.21 
(±0.08) respectively. The polydispersity values of all pools produced by RI detector were 
comparable to those obtained by UV detector with the same rank order. Polydispersity is 
a measure of the homogeneity of the fractions making up the heparin sample. For each of 
the heparins, the polydispersity decreased as the molecular weight decreased. The overall 
data of these studies showed that, bovine, ovine and porcine have comparable molecular 
weight profiles.  
Heparinase-I Degradation. The effects of heparinase-I digestion on the 
physicochemical properties of various heparin pools were subjected to heparinase-I 
digestion. Previous studies have shown (Xiao et al., 2011), that heparinase 1 cleaves 
heparins at both the GlcNS6S (1 → 4) IdoA2S and GlcNS3S6S (1 → 4) IdoA2S linkages 
(see ‘List of Abbreviations’ for full description). Interestingly, Xiao et al (2011) 
demonstrated that heparinase I had selectivity for the GlcNS3S6S (1 → 4) IdoA2S 
linkages, which were found primarily within the antithrombin binding sites, compared to 
the major disaccharide repeating unit GlcNS6S (1 → 4) IdoA2S. 
In this study, heparinase digestion resulted in the fragmentation of each agent into 
its oligosaccharide components; mainly, di, tetra, hexa, octa, and deca saccharides for all 
the heparin pool samples.  
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In Figures 5 & 6, Panel A shows the elution profiles for the non-digested samples, 
while Panel B shows the elution profiles for the heparinase digested samples using the 
UV detection and RI detection methods, respectively. As seen in Figures 5 & 6, 
heparinase-I was clearly capable of depolymerizing the various heparin pools as evident 
by the shift to the right of each peak and subsequent decrease in mean molecular weight 
for all agents (B). Additionally, the similar post-digested mean molecular weights 
(ranging from 2.9 to 3.2 kDa) for each heparin pool demonstrates a similar degree of 
heparinase digestion.  
The calculated molecular weights for pre and post heparinase digestion samples 
were comparable with the UV and RI detectors. The results for the pre and post 
heparinase digestion of BMH, OMH and PMH pools, obtained with the UV and RI 
detectors for the NRC method, are tabulated in Table 5. All post heparinase digestion 
pools showed comparable molecular weights as determined by UV and RI detections. 
Heparinase digestion-index of OMH (80%), PMH (83%) and BMH (86%) heparins were 
comparable when using UV detection. The same trend was noted when using RI 
detection.   
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A. Pre-heparinase digestion 
 
 
B. Post-heparinase digestion 
 
 
 
Figure 5. Heparinase digestion of bovine (black), ovine (blue) and porcine (green) pools 
as measured by GPC using the NRC method.  Pre (A) and Post (B) heparinase elution 
profiles were determined using the UV detection method. Heparinase (1 U/ml final 
concentration) was incubated with various heparins (10 mg/ml, pH = 5.0) at 37°C for 30 
min. 
 
 
 
  
A
U
-0.002
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
0.022
0.024
0.026
Minutes
21.0 24.0 27.0 30.0 33.0 36.0 39.0 42.0 45.0
A
U
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
Minutes
21.0 24.0 27.0 30.0 33.0 36.0 39.0 42.0 45.0 48.0 51.0 54.0
48 
 
 
A. Pre-heparinase digestion 
 
 
 
B. Post-heparinase digestion  
 
 
 
Figure 6. Heparinase digestion bovine (black), ovine (blue) and porcine (green) pools as 
measured by GPC using the NRC method.  Pre (A) and Post (B) heparinase elution 
profiles were determined using the RI detection method. Heparinase-1 (1 U/ml final 
concentration) was incubated with various heparins (10 mg/ml, pH = 5.0) at 37°C for 30 
min. 
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Nuclear Magnetic Resonance 
BMH, OMH and PMH pools were investigated using one and bi dimensional 
NMR methods. Proton and carbon assignments were made using 2D-NMR. Figures 7 and 
8 showed the proton and carbon NMR spectra of heparin pools prepared from porcine, 
bovine and ovine species. The spectral data were consistent with previously published 
spectra of the same types of heparins (K. St. Ange et al.,2016) and (L. Fu, et al,.2013). 
            1H Spectrum (Proton NMR). Figure 8 showed the proton NMR spectra (1H 
Spectrum) of the various heparin pools. The Peak/ppm/assignment/residue were as 
follow; A/5.51/H1/GlcNS6S; B/5.38/H1/GlcNS3S; C/5.34/GlcNY6X (where Y = Ac or 
S and X = H or S); D/5.15/H1/IdoA2S; E/4.93/H1/ IdoA2S–GlcNS6S; E2/4.85/H1/ 
IdoA2S–GlcNS; F/4.67/H5/ IdoA2S; G/4.53/H1/GlcA; H/4.34/H6/GlcNS6X; 
I/4.26/H2/IdoA2S; J/4.19/H6/GlcNS6S; K/4.13/H3/IdoA2S; L/4.03/H4/IdoA2S; 
M/3.94/H5/GlcNS6S; N/3.78/H6/GlcNS; O/3.71/H4/GlcNS6S;   P/3.58/H3/GlcA; 
Q/3.32/H2/GlcA,GlcNS3SandGlc3 S; R/3.20/H2/GlcNS6X; S/1.95/CH3/GlcNAc. 
The A-S assignments represent nineteen individual peaks in the porcine heparins in this 
analysis. These peaks were used to reference the observed peaks to compare the BMH 
and OMH preparations. For OMH, peak D was slightly higher and peak S was slightly 
lower compared to PMH and BMH. In addition, no unidentified peak was observed in 
OMH. However, for BMH, there were 2 peaks between peak C and peak D, one peak 
next to peak F that were not present in PMH and OMH. 
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          13C Spectrum (Carbon NMR).   Figure 9 showed the carbon NMR spectra (13C 
Spectrum). 13C hydrogen decoupled NMR experiments were performed on the samples 
for 2000 scans. Peak/ppm/assignment/residue were noted as follow; A/101.97/C1/GalA; 
B/99.39/C1/IdoA2S; C/96.70/C1/GlcNS and GlcNAc; D/66.37/C6/GlcNS2S; 
E/61.10/C6/GlcNS2S–OH; F/57.91/C2/GlcNS; G/22.00/CH3/GlcNAc.  
 The A-G peaks represent seven components as detected by this method. They 
were used as reference to compare BMH, OMH and PMH preparations. For the most 
part, the 13C NMR spectra of the OMH and PMH were comparable. In contrast, the 13C 
NMR spectrum of BMH was significantly different, especially in the region between 50 
to 100 ppm. 
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1H NMR Spectra 
 
 
 
Figure 7. Shows the proton NMR spectra (1H Spectrum) of pools prepared from porcine, 
bovine and ovine heparins. 1H NMR experiments were performed on the samples for 32 
scans with a five seconds relaxation delay. 
 
 
13C NMR Spectra 
 
 
 
Figure 8. Shows the carbon NMR spectra (13C Spectrum) of pools prepared from 
porcine, bovine and ovine heparins. 13C hydrogen decoupled NMR experiments were 
performed on the samples for 2000 scans.  
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In Vitro studies for functional profiling of heparins 
The pharmacological actions of UFHs are predominately the result of their 
interactions with a diversity of plasma proteins and the inhibition of serine protease 
including factor Xa and thrombin. The ability of heparins to inhibit various serine 
proteases is predominately mediated by the cofactors, AT and HCII. The binding of 
heparins with AT and HCII is strongly influenced by the molecular weight (MW) and 
structural composition of each heparin.  
In this section, the effect of various heparins on anticoagulation and antiprotease 
activity were determined using well-defined biochemical systems in which various 
unfractionated heparins (UFHs) from different sources were supplemented in blood bank 
plasma (BBP) at various concentrations, in order to determine the anticoagulant and 
antiprotease properties of these agents.  
Global anticoagulant assays 
aPTT test. The anticoagulant effects of PMH, OMH and BMH as measured by 
aPTT are shown in Figure 9.  All agents were supplemented in BBP over a concentration 
range of 0 to 10 µg/ml. OMH and PMH exhibited significant anticoagulant effects at 
concentrations above 2.5 µg/ml compared to BMH. At concentrations above 5 µg/ml 
BMH produced significantly longer clotting times compared to baseline values. While the 
OMH and PMH provided comparable results, the BMH exhibited lower activities (Tables 
6 & 7). 
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B. aPTT test – various batches 
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Figure 9. Comparative anticoagulant effects in blood bank plasma (BBP) as measured by 
the APTT assay. Heparin pools (A) and heparin means (B). All agents were 
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Ovine and porcine 
heparins exhibited significant (*p <0.05) anticoagulant effects at the 5 µg/ml 
concentration compared to bovine ones. Additionally, ovine and porcine heparin pools 
(A) produced longer clotting times compared to bovine heparin pool at all concentrations 
except at 10 µg/ml. 
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5U Ca2+ TT.  Figure 10 shows the anticoagulant effects of various UFHs as 
measured by the 5U Ca2+ TT assay after supplementation in BBP. As seen in panel A, 
OMH and PMH pools exhibited significant anticoagulant effects at the 1.25 µg/ml 
concentration, while BMH exhibited significant anticoagulant effects at 2.5 µg/ml 
concentration compared to baseline values. The various heparin batches exhibited the 
same trend as shown in panel B.  
In the 5U Ca2+ TT assay, differences in the anticoagulant activities of the various 
UFHs in BBP were noted (Tables 8 & 9). However, at concentrations above 1.25 µg/ml, 
the anticoagulant effects of OMH and PMH were comparable. The overall anticoagulant 
effects of the BMH in the 5U Ca2+ TT assay was lower compared to OMH and PMH at 
concentrations lower than 1.25 µg/ml. 
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A. TT test - various pools 
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B. TT test - various batches 
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Figure 10. Comparative anticoagulant effects in blood bank plasma (BBP) as measured 
by the TT (5U Ca2+) assay. Heparin pools (A) and heparins mean (B). All agents were 
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Ovine and porcine 
heparins exhibited significant (p <0.05) anticoagulant effects at the 1.25 µg/ml 
concentration, while bovine heparins exhibited significant (p <0.001) anticoagulant 
effects at 2.5 µg/ml concentration. 
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Chromogenic antiprotease assays 
The inhibition of factor Xa and thrombin by various UFHs at a concentration 
range from 0 to 10 µg/ml was studied. Antiprotease actions of these agents were 
determined by amidolytic assays, which utilized substrates for factor Xa (Spectrozyme 
Xa) and thrombin (Spectrozyme TH). Optical density changes were used to determine the 
percent inhibition by each agent as compared to BBP.  
Anti-Xa assays. As seen in Figure 11, PMH and OMH pools when supplemented 
in BBP exhibited comparable anti-Xa activity at concentrations higher than 2.5 µg/ml 
(Panel A). PMH and OMH inhibited factor Xa at the highest concentration (10 µg/ml) by 
93.7 (±1.2) and 97 (±1.5) respectively. In contrast, BMH pool exhibited the lowest anti-
Xa activity compared to other pools and inhibited factor Xa at its highest concentration 
by 89.2 (±0.4). A similar trend was observed for the various heparin batches throughout 
the concentration range from 0 to 10 µg/ml (Panel B). The percentage inhibition of factor 
Xa for all heparin agents were noted at Tables 10 & 11.  
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Figure 11. The inhibition of factor Xa in blood bank plasma (BBP) as measured by the 
amidolytic anti-Xa assay. Heparin pools (A) and heparins mean (B).  All agents were 
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Porcine and ovine 
heparins showed comparable activities and both were more potent inhibitors of factor Xa 
than bovine heparins (p <0.01). 
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Anti-IIa assays. Figure 12 shows the effect of various heparins on the inhibition 
of thrombin after supplementation in BBP over a concentration range of 0 to 10 µg/ml. 
PMH and OMH pools significantly inhibited thrombin to a greater extent than bovine 
pool (Panel A). 
As shown in Table 12, at the concentration of 10 µg/ml, PMH and OMH pools 
inhibited factor IIa by 84.2% (±0.7) and 89% (±0.5) respectively. While the BMH 
inhibited factor IIa by 76% (±1.3) at the same concentration. The same trend was noted 
among the various heparin batches at the concentration of 10 µg/ml as shown in Table 
13. The OMH and PMH batches exhibited comparable anti-IIa activities while, the BMH 
batches showed lower anti-IIa activity. 
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B. Anti-IIa - various batches 
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Figure 12. The inhibition of thrombin in blood bank plasma (BBP) as measured by 
the amidolytic anti-IIa assay. Heparin pools (A) and heparins mean (B).  All agents 
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Porcine 
and ovine heparins showed comparable activities and both were more potent 
inhibitors of thrombin than bovine ones (p <0.03). 
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Chromogenic antiprotease assays (BioMed kits) for USP potency 
The USP potency was determined in accordance with the specifications and 
directions provided by the manufacturers (HYPHEN BioMed). Dilutions of the drugs 
were prepared in an antithrombin (AT)-supplemented buffer at concentrations 
ranging from 0 – 10 µg/mL. The drugs were compared using anti-Xa and anti-IIa 
assays. All results were plotted in terms of concentration effect curves. As shown in 
Figures 13 & 14, PMH and OMH pools showed comparable anti-Xa and anti-IIa 
potencies compared to the BMH pool. USP potency results of all heparin pools as 
determined by the chromogenic anti-Xa and anti-IIa assays were noted in Tables 14 
&15.  The USP potency of PMH pool as measured by anti-Xa assay was 190 ±1.4 
U/mg, whereas the OMH pool exhibited comparable potency of 197 ±2.8 U/mg. In 
contrast, the USP potency of the BMH pool was much lower (135 ± 2.1 U/mg). The 
USP potency as measured by anti-IIa assay showed the same trend. OMH and PMH 
pools exhibited comparable potencies of 200 ±1.2 U/mg and 186 ± 1.4 U/mg 
respectively. However, the BMH pool exhibited lower potency of 131 ± 1.3 U/mg 
compared to others. The anti-Xa - IIa ratio for all heparins pools were comparable. 
The various heparin batches showed the same trend in term of anti-Xa, Anti-IIa and 
anti Xa-IIa ratio (Table 15). 
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A. USP potency of various pools - anti-Xa assay 
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B. USP potency of various batches - anti-Xa assay  
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Figure 13. Comparative USP potencies as measured by the chromogenic anti-Xa 
assay (Hyphen Kits). Heparin pools (A) and heparins mean (B). The USP potency of 
porcine and ovine heparins were comparable. In contrast, the USP potency of the 
bovine heparins was significantly lower compared to others (*p <0.05). 
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A. USP Potency of various pools – anti-IIa assay 
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B. USP potency of various batches – Anti-IIa assay 
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Figure 14. Comparative USP potencies as measured by the chromogenic anti-IIa assay 
(Hyphen Kits). Heparin pools (A) and heparins mean (B). The USP potency of porcine 
and ovine heparins were comparable. In contrast, the USP potency of the bovine heparins 
was significantly lower compared to others (*p <0.05). 
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AT supplemented system Assays 
A standard method used in the Hemostasis and Thrombosis Research Lab was 
employed to determine the anti-Xa and anti-IIa activities in an AT supplemented 
system (see materials and methods). UFHs were supplemented in a purified AT 
system over a concentration range of 0-10 µg/mL and were mixed with a known 
amount of thrombin or factor Xa. The potency of each agent is presented in terms of 
IC50 (Tables 16 &17). Briefly, concentration verses percent inhibition was plotted and 
the linear portion of each curve was used to determine the IC50 value by extrapolating 
the concentration required to produce 50% inhibition. 
Figure 15 shows that PMH and OMH pools, when supplemented in AT system, 
exhibited the highest anti-Xa potency with IC50 values of 2.72 (±0.04) µg/ml and 
2.26 (±0.06) µg/ml, respectively, while BMH pool was significantly weaker to inhibit 
factor Xa with IC50 value of 3.7 (±0.07) µg/ml (Panel A). Figure 16 also shows the 
effect of the various pools on the inhibition of thrombin after supplementation in AT 
system. Again, PMH and OMH pools showed the highest anti-IIa potency with IC50 
values of 0.32 (±0.02) and 0.28 (±0.01) respectively, while the BMH pool was 
significantly weaker to inhibit factor IIa with IC50 value of 0.50 (±0.01) (Panel A). 
The same trend was noted with the various heparin batched as shown in Panel B. The 
values of IC50 of heparin means were noted in Table 17. 
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A. IC50 Values of anti-Xa and anti-IIa - various pools 
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B. IC50 values of anti-Xa and anti-IIa - means of various batches 
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Figure 15. Potency (IC50) comparison for various heparin agents when supplemented in 
purified AT system as measured by the amidolytic anti-Xa and anti-IIa assays. Heparin 
pools (A) and heparins mean (B). All agents were supplemented in the purified AT over a 
concentration range of 0 to 10 µg/ml. Porcine and ovine heparins showed comparable 
IC50 values and both were more potent inhibitors of factor Xa and thrombin than bovine 
heparins (*p <0.03). 
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Neutralization studies 
UFH are widely used anticoagulants for interventional and surgical use. As such, 
the ability to reverse the biological effects of heparins is very important. The 
anticoagulant and bleeding effects of heparin are clinically neutralized by protamine 
sulfate.  
The objective of this study was to determine the neutralization profiles of various 
heparin antagonists, such as heparinase-1 and protamine sulfate (PS). Protamine sulfate 
was added to the heparin solutions to obtain a final antagonist concentration of 10 μg/ml. 
whereas heparins were supplemented at 0 to 10 µg/ml range. For the heparinase-1 
digestions study, agents were supplemented in BBP at a concentration range of 0 to 10 
µg/ml. The heparin solutions were then supplemented with heparinase-1 to obtain a final 
heparinase-1 concentration of 1U. The neutralization effects were measured using the 
APTT, TT (5U Ca2+), anti-Xa and anti-IIa assays, which were previously discussed in the 
‘Materials and Methods’ section. The data represent the mean ± standard deviation of two 
independent experiments. 
Protamine sulfate neutralization. Figure 16 shows the in vitro neutralization of 
PMH, OMH and BMH pools by protamine as determined by the anticoagulant aPTT and 
TT assays. In the APTT assay (Panel A), PS (10 μg/ml) was able to completely neutralize 
the anticoagulant effects of the different concentrations of heparins at or below 5 μg/ml. 
As shown in Panel B, again PS was able to completely neutralize the anticoagulant 
effects of the different concentrations of heparins at or below 5 μg/ml. However, at 10 
μg/ml, PS failed to neutralize the anticoagulants effects of all heparins. 
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As shown in Figure 17, the same trend was observed for the amidolytic anti-Xa 
and anti-IIa assays. PS was able to completely neutralize the different heparin pools at 
concentrations below 5 μg/ml (Panels A & B). The results for the PS neutralization 
profile of PMH, OMH and BMH pools, are tabulated in Tables 18, 19 & 20 respectively. 
Heparinase-1 digestion. The neutralization of various heparin pools by 
heparinase (HP) as measured by the APTT and TT assays are shown in Figure 18. When 
determined by the APTT assay (Panel A), HP strongly neutralized the anticoagulant 
effects of all heparin pools. The same trend was noted for TT assay (Panel B).  
As shown in Figure 19, hepariase-1 (HP) was able to completely neutralize all 
heparin pools at all concentration points as determined by the amidolytic anti-Xa and 
anti-IIa assays (Panels A & B). These results indicate that, heparinase I cleaved 
selectivity the GlcNS3S6S (1 → 4) IdoA2S linkages, which are present primarily within 
the antithrombin binding sites. The results for the heparinase-1 neutralization profile of 
PMH, OMH and BMH pools, are tabulated in Tables 21, 22 & 23 respectively. 
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Figure 16. Comparative neutralization profile of various heparin pools using protamine 
sulfate as determined by the anticoagulant aPTT and TT assays. APTT assay (A) and TT 
assay (B). All agents were supplemented in BBP over a concentration range of 0 to 10 
µg/ml. Protamine sulfate was added to the heparin supplemented plasma to obtain a final 
protamine concentration of 10 μg/ml. As seen in panels A and B, protamine sulfate 
completely neutralized all heparin pools at concentrations at or below 5 μg/ml. aPTT, 
activated partial thromboplastin time; TT, thrombin time. 
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B. Anti-IIa assay 
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Figure 17. Comparative neutralization profile of various heparin pools using protamine 
sulfate as determined by the amidolytic anti-Xa and anti-IIa assays. Anti-Xa (A) and anti-
IIa (B). All agents were supplemented in BBP over a concentration range of 0 to 10 
µg/ml. Protamine sulfate was added to the heparin supplemented plasma to obtain a final 
protamine concentration of 10 μg/ml. As seen in panel A and B, protamine sulfate 
completely neutralized all heparin pools at concentrations at or below 5 μg/ml. Xa, factor 
Xa: IIa, thrombin. 
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Figure 18. Comparative neutralization profile of various heparin pools using heparinase-
1 as determined by the anticoagulant aPTT and TT assays. APTT assay (A) and TT assay 
(B). Heparinase-1 (1 U/ml final concentration) was incubated with various heparin pools 
(10 mg/ml, pH = 5.0) at 37°C for 30 min. As seen in panels A and B, heparinase-1 
completely neutralized all heparin pools at all concentration points. aPTT, activated 
partial thromboplastin time; TT, thrombin time. 
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A. Anti-Xa assay 
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B. Anti-IIa assay 
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Figure 19. Comparative neutralization profile of various heparin pools using 
heparinase-1 as determined by the amidolytic anti-Xa and anti-IIa assays. Anti-Xa 
(A) and anti-IIa (B). Heparinase-1 (1 U/ml final concentration) was incubated with 
various heparin pools (10 mg/ml, pH = 5.0) at 37°C for 30 min. As seen in panels A 
and B, heparinase-1 completely neutralized all heparin pools at all concentration 
points. Xa, factor Xa; IIa, thrombin. 
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Heparin induced thrombocytopenia (HIT) screening 
Heparin induced thrombocytopenia (HIT) is a clinical event where antibody 
mediated platelet aggregation occurs due to the presence of antibodies reactive against 
the platelet factor 4 (PF4)/heparin complex. The reactive antibodies occur due to current 
or previous exposure to heparin. Activation of platelets induces the release of 
microparticles and ultimately leads to a reduction in the number of platelets, which is 
termed thrombocytopenia. The purpose of this study was to examine the effects of 
different heparin pools on HIT positive (+) antibody mediated aggregation of platelets 
and how molecular weight and structural differences among these agents may contribute. 
Platelet rich plasma (PRP) was incubated with the different heparin agents (final 
concentrations of 10, 1 and 0.1 µg/ml) and serum from a known HIT positive pool. 
Aggregation of platelets upon addition of the various heparin pools indicated a positive 
HIT potential. Results from these studies are compiled in Table 24. 
The effects of various heparin pools on HIT+ antibody mediated platelet 
aggregation is depicted in Figure 20. In the control PRP, saline was only supplemented 
with HIT + serum, 5 % (±1.2) aggregation was observed. All pools produced significant 
platelet aggregation compared to control at concentrations of 10 and 1 µg/ml. However, 
none of the pools showed a platelet aggregation response at 0.1 µg/ml. These results 
suggest that all heparin pools have a similar HIT profile at the same concentrations. 
Figure 21 depicts the effect of various heparin pools pre and post heparinase-1 
digestion on HIT positive antibody platelet aggregation. All pre heparinase digestion 
pools showed comparable platelet aggregation responses at concentrations of 10 and 1 
µg/ml, however all pools showed no HIT response at 0.1 µg/ml. All post heparinase 
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digestion pools showed no platelet aggregation responses at all concentrations. These 
results suggest that, heparinase-1 completely neutralizes heparins from various animal 
sources. Results from these studies are compiled in Table 25. 
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Figure 20. The effect of various heparin pools on HIT antibody mediated platelet aggregation. All agents were tested at final 
concentrations (FC) of 10 ,1 and 0.1 µg/ml. All agents produced significant platelet aggregation compared to saline (negative 
control) at concentrations of 10 and 1 µg/ml, with no significant differences between each agent (Panels A &B). While at 0.1 
µg/ml, all agents showed no platelet aggregation response (Panel C). AA was used as a positive control. AA, arachidonic acid; 
FC, final concentration. The data represent the mean ± standard deviation (n=5 platelet donors). 
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Figure 21. The effect of various heparin pools pre and post heparinase-1 digestion on HIT positive antibody platelet 
aggregation. All agents were tested at final concentrations of 10 ,1 and 0.1 µg/ml. Post digested heparin pools exhibited no 
platelet aggregation responses at all concentrations. AA was used as a positive control. AA; arachidonic acid, FC; final 
concentration, PP; porcine pool, BP; bovine pool, OP; ovine pool. The data represent the mean ± standard deviation (n=5 
platelet donors).  
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In Vivo studies in non-human primates 
 Non-human primates can be used to study the pharmacodynamic and 
pharmacokinetic properties of various heparins in an in vivo model similar to humans. To 
elucidate how molecular weight and structure contribute to the pharmacodynamic and 
pharmacokinetic properties, various heparin pools were given to primates intravenously 
(IV) at doses previously described in the ‘Materials and Methods’ section. The 
pharmacokinetic and pharmacodynamic profiles of PMH, OMH and BMH pools were 
assessed using a variety of clotting and amidolytic assays (results shown in Appendix). 
 Concentration-response curves were made by supplementing various heparin 
pools in pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml. 
Best-fit curves were made and the drug concentration in plasma samples collected at 
various time points following heparin administration was determined by extrapolation 
using the measured percent inhibition of factor Xa and thrombin.  
 The results are presented as the mean ± SD. Compiled data for the individual 
experiments can be found in Tables 25 and 26 through in Appendix. 
1. Comparative pharmacodynamic investigation of various heparin pools 
 In Figure 22, panel A depicts the aPTT response curves after 500 µg/kg IV 
administration of various heparin pools to primates. OMH and PMH pools significantly 
prolonged the clotting time compared to BMH pool at 15, 30, and 60 minutes. Maximal 
effects for OMH pool (39.8 ± 2.3 sec) and PMH pool (38.8 ± 1.0 sec) were seen at 15 
minutes post drug administration (PDA), while the BMH pool demonstrated maximal 
anticoagulant effect (33.6 ± 2.9 sec) at 15 minutes PDA.  
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 In the aPTT assay where the PMH and OMH pools showed comparable 
anticoagulant effects, BMH pool consistently showed lower effect at all time points. The 
TT response curves are shown in panel B. OMH and PMH pools significantly prolonged 
the clotting time at 60 minutes compared to the BMH pool. The plasma concentration-
time courses for each agent as determined by effects on aPTT and TT prolongation are 
shown in Table 26. 
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Figure 22. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine 
pools administered to primates as measured by the anticoagulant aPTT and TT assays. 
APTT assay (A) and TT assay (B). As seen in panel A, ovine and porcine pools 
significantly prolonged the clotting time compared to the bovine pool (*p <0.05). Panel 
B shows that ovine and porcine pools were significantly more effective than bovine pool 
at prolonging the clotting time at 60 minutes (*p <0.03). The data represent the mean (±) 
standard deviation (n=4). 
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           The time courses of the amidolytic anti-Xa activity of PMH, OMH and BMH 
pools (500 µg/kg IV) are shown in Figure 23. In panel A, the anti-Xa activity expressed 
as % inhibition at various time points is shown. At 30 and 60 minutes post-drug 
administration, OMH and PMH pools led to significantly higher levels of factor Xa 
inhibition compared to BMH pool. At 120 minutes post-drug administration, anti-Xa 
activity of all agents were comparable. Peak anti-Xa activity for OMH and PMH pools 
were (90.5 ±7.1 % Inh) and (88.5 ±5.5 % Inh) respectively. However, the peak anti-Xa 
activity for the BMH pool was the lowest (79.3 ±6.3 % Inh).  
 Panel B shows the plasma concentration-time courses for each agent as 
determined by their effects on anti-Xa activity. The peak plasma concentrations achieved 
following administration of OMH pool (2.3 ± 0.1 U/ml) and PMH pool (2.2 ± 0.1 U/ml) 
were significantly greater than after the administration of the BMH pool (1.5 ± 0.1 U/ml).  
 The time courses of the amidolytic anti-IIa activity of PMH, OMH and BMH 
pools (500 µg/kg IV) are shown in Figure 24. In panel A, the anti-IIa activity expressed 
as % inhibition at various time points is shown. At 15, 30, 60 and 120 minutes post-drug 
administration, OMH and PMH pools produced a significantly higher level of thrombin 
inhibition compared to the BMH pool. Peak anti-IIa activities for OMH and PMH pools 
were (92.3 ±2.5 % Inh) and (89.5 ±3.4 % Inh) respectively. However, the peak anti-IIa 
activity for the BMH pool was the lowest (80.5 ±2.6 % Inh).  
 Panel B shows the plasma concentration-time courses for each agent as 
determined by their effects on anti-IIa activity. The peak plasma concentrations following 
administration of OMH pool (2.2 ± 0.1 U/ml) and PMH pool (1.9 ± 0.3 U/ml) were 
significantly greater (p < 0.001) than after BMH pool (1.2 ± 0.2 U/ml). The % inhibition 
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results of anti-Xa and anti-IIa activities for all agents are shown in Table 26. The plasma 
concentration-time courses for each agent as determined by the amidolytic anti-Xa and 
anti-IIa activities are shown in Table 27. 
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B. Anti-Xa - U/ml 
 
 
Figure 23. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine 
pools administered to primates as measured by the anti-Xa assay. As seen in panel A, 
ovine and porcine pools significantly inhibited factor Xa activity at 30 and 60 minutes 
compared to the bovine pool. Panel B shows the plasma concentration-time courses of 
each agent as determined by effects on anti-Xa activity. At 15 and 30 minutes, the plasma 
concentrations of ovine and porcine pools were significantly greater than the bovine pool 
(*p <0.05). The data represent the mean (±) standard deviation (n=4). 
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A. Anti-IIa - % inhibition 
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B. Anti-IIa - U/ml 
 
 
Figure 24. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine 
pools administered to primates as measured by the anti-IIa assay. As seen in panel A, 
ovine and porcine pools significantly inhibited thrombin activity compared to the bovine 
pool (*p <0.05). Panel B shows the plasma concentration-time courses of each agent as 
determined by effects on thrombin activity. At 15, 30 and 60 minutes, the plasma 
concentrations of ovine and porcine pools were significantly greater than the bovine pool 
(*p <0.05). The data represent the mean (±) standard deviation (n=4). 
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Comparative pharmacokinetic investigation of various heparin pools 
     The estimation of pharmacokinetic parameters calculated from plasma concentration-
time curves using the anti-Xa assay after IV administration of 500 µg/kg heparin pools to 
non-human primates are shown in Figure 25. At the indicated dose, BMH pool (96 ± 13 
mins) demonstrated a significantly longer half -life (t1/2) compared to PMH (60 ± 8 mins) 
and OMH (40 ± 6 mins) pools (A). No differences in area under the curve (AUC) were 
noted between each agent (B). Although BMH pool appeared to have a larger volume of 
distribution (Vd), no significant differences were noted between each agent (C). No 
differences in systemic clearance (Cl) were noted between each agent (D). 
     The estimation of pharmacokinetic parameters calculated from plasma concentration-
time curves using the anti-IIa assay after IV administration of 500 µg/kg heparin pools to 
non-human primates are shown in Figure 26. At the indicated dose, BMH pool (105 ± 14 
mins) demonstrated a significantly longer half -life (t1/2) compared to PMH (58 ± 8 mins) 
and OMH (40 ± 3 mins) pools (A). No differences in area under the curve (AUC) were 
noted between each agent (B). However, BMH pool (60 ± 8 ml/kg) exhibited a 
significant larger volume of distribution (Vd) compared to PMH (38 ± 6 ml/kg) and 
OMH (33 ± 6 ml/kg) pools (C). No differences in systemic clearance (Cl) were noted 
between each agent (D). The results for the pharmacokinetic parameters of porcine, 
bovine and ovine pools, are tabulated in Table 28. 
 In both anti-Xa and anti-IIa assays the relative concentration 15 mins after the 
administration of OMH and PMH were higher than BMH. In anti-Xa assay, Cmax of OMH 
(2.3 U/ml) and PMH (2.2 U/ml) heparins were significantly higher compared to the BMH 
(1.5 U/ml). The same trend was noted in the anti-IIa assay, where the Cmax of OMH and 
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PMH were 2.2 U/ml and 1.9 U/ml respectively. In contrast, the BMH showed lower Cmax 
of 1.2 U/ml compared to the others.   
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Anti-Xa assay 
 
 
Figure 25. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after IV administration of 500 µg/kg 
heparin pools to non-human primates. In panel A, bovine pool demonstrated a 
significantly longer half -life compared to porcine and ovine pools (*p <0.05). No 
significant differences in area under the curve, volume of distribution and clearance 
between all pools as shown in panels B, C and D respectively. The data represent the 
mean (±) standard deviation (n=4).  
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Anti-IIa assay 
 
 
Figure 26. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-IIa assay after IV administration of 500 µg/kg 
heparin pools to non-human primates. In panel A, bovine pool demonstrated a 
significantly longer half -life compared to porcine and ovine pools (*p <0.05). No 
significant differences in area under the curve and clearance between all pools as shown 
in panels B and D respectively. As shown in panel C, bovine pool exhibited a significant 
larger volume of distribution (Vd) compared to porcine and ovine pools (*p <0.05). The 
data represent the mean (±) standard deviation (n=4).  
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CHAPTER FIVE 
DISCUSSION 
 
Heparin, also known as unfractionated heparin (UFH), is a medication which 
has been used as an anticoagulant and antithrombotic agent for over 80 years. It was 
the first systemic anticoagulant used in the management of various thrombotic disorders 
such as deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. 
Heparin is a heterogeneous drug in terms of its molecular weight (MW), structural 
composition, and its biological actions. Preparations of heparin can contain fractions 
that vary in molecular weight from 1.5 kDa to 30 kDa (Nader et al., 1974).  
    Most UFHs are derived from porcine intestinal mucosa, however, heparin has 
also been manufactured from other mammalian sources such as bovine (cow) and ovine 
(sheep) tissues. Nowadays, there are some concerns about a shortage of porcine heparin 
as it is widely used in the manufacturing of the low molecular weight heparins 
(LMWHs). Also, open-heart surgeries, hemodialysis and interventional cardiovascular 
procedures are usually carried out utilizing unfractionated heparin. Moreover, due to 
cultural and religious reasons in some countries, alternative sources of heparins are 
needed. The FDA and other regulatory agencies are currently considering the 
introduction of bovine unfractionated heparin for parenteral indications. 
In this dissertation, the differences among bovine, ovine and porcine heparins were 
investigated by comparing the biochemical and pharmacological effects of these 
heparins in a variety of in vitro assays and in vivo animal models. 
 The initial studies consisted of molecular and compositional analyses which 
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provided crucial data on the physicochemical characteristics of these agents. A 
comprehensive biochemical analysis included extensive testing of the in vitro 
anticoagulant and antiprotease actions in plasma-based systems. The purpose of these 
studies was to determine the extent of biosimilarity between bovine, ovine, and porcine 
heparins. 
Physicochemical characterization of various heparins 
Gel-permeation chromatography 
Molecular weight profiles. As BMH, OMH and PMH are heterogeneous in 
nature, their average molecular weights can be determined by using size exclusion 
chromatography (SEC). SEC separates the components of the different heparins based 
on MW, while offering the advantages of minimal sample preparation and a rapid 
turnaround time (Ahsan et al., 1995). In this dissertation, in order to obtain MW data 
from the HPLC elution profiles, calibration of the columns was performed using a set 
of narrow range calibrators (NRC) consisting of thirteen fractions of heparin with 
varying MWs ranging from 1.1 to 32 kDa. The MWs of these calibrators have been 
previously reported (Ahsan et al., 1994).  
Using the NRC method, with a few minor exceptions, the MWs determined by 
the UV and RI detectors compared well. Therefore, the discussion on MW 
determination will be based on data collected using the UV detector. The mean of 
weight average molecular weight (Mw) of BMH (21.9 ±3.8 kDa) was slightly higher 
compared to PMH (18.6 ±5.3 kDa) and OMH (18.2 ±2.6 kDa). The polydispersity, 
which is a measure of heterogeneity, was slightly higher for BMH (1.35 ±0.07) than for 
all other agents. In summary, these studies demonstrated a comparable molecular 
weight profile of BMH, OMH and PMH. The other physiochemical parameters used to 
characterize molecular weight profile of heparin were also comparable for all agents. 
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Heparinase-I degradation. Heparinase-I cleaves heparins between the 2-sulfo-
iduronate and 2,6-disulfo- glucosamine residues (Nader et al., 1999; Xiao et al., 2011). 
Overall, heparinase-I was clearly capable of depolymerizing the various heparins as 
evident by the shift to the right of each peak and subsequent decrease in mean molecular 
weight for all agents. Additionally, the similar post-digested mean molecular weights 
(ranging from 2.9 to 3.2 kDa) for each heparin demonstrates a similar degree of 
heparinase-I digestion. Moreover, the heparinase digestion indexes for all heparins 
were comparable. Therefore, each of the three UFH’s were digested by heprinase-I in 
a comparable fashion, suggesting a comparable amount of 2-sulfo-iduronate 2,6-
disulfoglucosamine linkages in the various heparins. 
Nuclear magnetic resonance (NMR) 
The 1H NMR spectra of PMH, OMH and BMH appeared largely comparable, 
however some differences were noted (L. Fu et al., 2013; V. Ruiz et al., 2002). 
Generally, in comparison to BMH, OMH is closer to PMH. PMH contained 
considerably more N-acetylated glucosamine residues than either OMH or BMH as 
seen by the relative intensity of the peak at δ 1.96 in the 1H NMR spectra (L. Fu et al., 
2013; M. Guerrini et al., 2001). In the anomeric region of the 1H NMR spectra, the 
signals of 3-O-sulfo-N-acetylglucosamine and 3-O-sulfo-N-sulfoglucosamine 
residues are useful for distinguishing among different species (L. Fu et al., 2013; V. 
Ruiz et al., 2002; M. Guerrini et al., 2001). Additionally, the relative amounts of 
iduronic acid and glucuronic acid residues are weakly dependent on the heparin 
species (L. Fu et al., 2013; V. Ruiz et al., 2002). Moreover, differences in sulfation at 
several specific positions (position 6 of glucosamine residues, position 3 of 
glucosamine, and position 2 of the iduronic acid) were found between PMH and BMH 
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(V. Ruiz et al., 2002; M. Guerrini et al., 2001). The peak D was slightly higher and 
peak S was slightly lower for OMH and no unidentified peak is observed. However, 
for BMH, there were 2 peaks between peak C and peak D, one peak next to peak F 
that was not present in PMH and OMH. In addition, peaks intensity from peak I to 
peak P were significantly different from PMH and OMH. Peak S intensity was also 
higher than that in PMH and OMH. However, this univariate spectrum evaluation 
does not provide enough information for the unambiguous characterization of 
heparin’s species of origin. In a previous study, the correlation of NMR spectra of 
heparin showed that PMH and OMH were similar in their profile (V. Ruiz et al., 
2002). In general, the 1H-NMR spectra of PMH and OMH were almost identical. Both 
can pass USP specification for heparin, which have been published in the 
pharmacopeia forum. 
            The 13C NMR spectra for PMH and OMH were almost identical. However, the 
level of 6-O-sulfation of the glucosamine residues of OMH was higher. A lower 
degree of acetylation was found in OMH in comparison to PMH and BMH. The 13C-
NMR spectrum of BMH was significantly different from that of PMH and OMH, 
especially in the region between 50 to 100 ppm. Peak D and peak E represent 
glucosamine 6-O-sulfation and glucosamine 6-OH, respectively. BMH had a lower 
degree of 6-O sulfation compared to PMH and OMH as evidenced by the higher 
intensity of peak E. 
In Vitro studies 
The therapeutic effects of heparins are predominately due to their interactions 
with a diversity of plasma proteins including factor Xa and thrombin. The ability of 
heparins to bind to and inhibit such serine proteases is predominately mediated by 
cofactors such as AT and HCII.  
The anticoagulant and antiprotease actions of BMH, OMH and PMH were 
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studied following supplementation in blood bank plasma (BBP). The anticoagulant and 
antiprotease effects were measured using the aPTT, thrombin time (TT), anti-Xa and 
anti-IIa assays. The aPTT assay has already been discussed (Methods and Materials). 
TT is a clot based assay which is designed to measure the conversion of fibrinogen to 
fibrin following the addition of a known amount of thrombin into plasma (O' Shea et 
al., 1971). This assay is primarily used to monitor antithrombin agents. In the current 
studies, thrombin was supplemented with calcium chloride to lower the sensitivity of 
the assay allowing for strong antithrombin drugs to produce a measurable effect. With 
the addition of calcium, the baseline clotting time is reduced to approximately 12 -15 
seconds from 20 seconds. Both the anti-Xa and Ila assays are chromogenic assays that 
use factor Xa or IIa specific substrates onto which a chromophore has been linked. 
Factor Xa or IIa cleaves the chromogenic substrate, releasing a colored compound that 
can be detected with a spectrophotometer. The amount of color formed is directly 
proportional to the amount of factor Xa or IIa present (Walenga and Hoppensteadt, 
2004). These assays are a direct measurement of the effects of heparins on factors Xa 
and thrombin only. 
Global anticoagulant assays 
        In the aPTT assay, the anticoagulant effects of OMH and PMH heparins were 
comparable and both exhibited significant anticoagulant effects at concentrations 
above 2.5 µg/ml compared to BMH. At concentrations above 5 µg/ml BMH produced 
significantly longer clotting times compared to baseline values. The concentrations of 
heparin needed to double the aPTT for OMH (1.21 µg/ml) and PMH (1.25 µg/ml) 
were lower compared to the BMH (1.9 µg/ml). 
       In the TT assay, OMH and PMH showed comparable anticoagulant effect and 
both exhibited significant clotting time prolongation at the 1.25 µg/ml concentration, 
91 
 
while BMH exhibited significant anticoagulant effects at a higher concentration (2.5 
µg/ml).  
Chromogenic antiprotease assays 
            The antiprotease activities of the heparins were measured in terms of the 
inhibition of factor Xa and thrombin at a concentration range from 0 to 10 µg/ml. 
PMH and OMH exhibited comparable anti-Xa activity at all concentrations. and both 
of them inhibited factor Xa at the highest concentration (10 µg/ml) by 93.7% (±1.2%) 
and 97% (±1.5%) respectively. In contrast, BMH exhibited a lower anti-Xa activity 
compared to the other heparins, and its maximal inhibition of factor Xa (89.2% 
±0.4%) was lower than that observed for PMH (93.7% ± 1.2%) and OMH (97% ± 
1.5%). 
The same pattern was noted with anti-IIa activity. At a concentration of 10 
µg/ml, PMH and OMH inhibited thrombin by 84.2% (±0.7%) and 89% (±0.5%) 
respectively. While BMH inhibited thrombin by 76% (±1.3%) at the same 
concentration. The overall results from these global anticoagulants and amidolytic 
antiprotease studies demonstrate that the BMH was consistently weaker than PMH and 
OMH samples.  
Chromogenic antiprotease assays (BioMed kits) 
         The USP potencies of the heparins were compared using chromogenic anti-Xa 
and anti-IIa assays. Anti-Xa and anti-IIa assays are two-step chromogenic methods 
based on the inhibition of a constant amount of factor Xa or factor IIa by the tested 
heparin in presence of exogenous AT (stage 1). Any excess factor Xa or factor IIa 
interacts with an enzyme specific chromogenic substrate (stage 2) to produce color, 
which is inversely proportional to the heparin activity (FXa-CS # 11-65 and FIIa-CS # 
01-38).  
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        The USP potency of PMH ranged from 189-190 U/mg, whereas the OMH 
exhibited comparable potencies in the range of 191-197 U/mg. In contrast, the USP 
potency of the BMH was much lower, ranging from 135-138 U/mg. The anti-Xa - IIa 
ratios for all heparins were comparable. Overall results from these studies showed that 
BMH has lower potency compared to OMH and PMH. 
AT supplemented system assays 
 
        BMH, OMH and PMH heparins were supplemented in a purified AT system 
over a concentration range of 0-10 µg/mL and were mixed with a known amount of 
thrombin or factor Xa. The potency of each agent is presented in terms of its IC50. As 
mentioned before, the IC50 value is the concentration required to produce 50% 
inhibition. 
         The IC50 values for OMH and PMH were significantly lower than that of BMH, 
as measured by both assays. These studies suggest that OMH and PMH are more 
potent than BMH. A possible explanation of this observation could be that BMH has a 
lower AT binding content compared to OMH and PMH which alters its ability to 
inhibit factor Xa and thrombin. This observation has been reported in an earlier 
publication (Naggi et al., 2015). 
Neutralization studies 
       Heparin, and its analogues, are used during surgery and dialysis, and are often 
used to coat indwelling catheters and other devices where the vascular system is 
exposed. As such, the ability to reverse the biological effects of heparins is of 
considerable importance. Presently, the anticoagulant and bleeding effects of heparin 
are neutralized by protamine sulfate. The objective of these studies was to determine 
the neutralization profiles of various heparin antagonists, such as protamine sulfate 
(PS) and heparinase-I. The neutralizing effects of these antagonists were measured by 
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comparing various clotting and antiprotease activities of heparins pre- and post-
neutralization. 
       Protamine sulfate neutralization (PS). Protamine sulfate (PS) is the main 
heparin antagonist that has been used clinically for many years. The interaction of 
protamine with heparin and its analogs have been extensively studied (Racanelli et al., 
1985).  
      In the anticoagulant aPTT and TT assays, PS was able to completely neutralize the 
anticoagulant effects of the different heparins at concentrations below 5 μg/ml.  
      In antiprotease assays, PS was able to completely neutralize the different heparins 
at concentrations below 5 μg/ml. However, at 10 μg/ml, the neutralization effects of 
PS were variable. These results showed that heparins from different animal sources 
have the same PS neutralization profiles. This is probably because OMH, BMH and 
PMH have chain lengths containing greater than 18 saccharides which is essential for 
optimal PS binding to heparin and its neutralizing effects (Harenberg et al., 1985; 
Holst et al., 1994). 
Heparinase-I digestion. Heparinase-I (HP) is an enzyme purified and 
characterized from Flavobacterium heparinum (Lohse and Lindardt, 1992). The 
cleavage of heparin by HP occurs at the linkage regions between the GlcNS6S (1→4) 
IdoA2S and GlcNS3S6S (1→4) IdoA2S residues (Xiao et al., 2011). Xiao et al (2011) 
demonstrated that the GlcNS3S6S (1→4) IdoA2S linkage, which is found mainly 
within the AT binding site, is more susceptible to cleavage by heparinase-1 than the 
major heparin disaccharide repeating unit GlcNS6S (1→ 4) IdoA2S. 
     These studies showed that the anticoagulant and antiprotease activities of all 
heparins (BMH, OMH and PMH) were completely neutralized by heparinase-I to 
almost the same degree. This is due to the exhaustive digestion of the chains present 
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in these heparins. 
Heparin induced thrombocytopenia (HIT) screening 
        One manifestation of heparin’s interactions with platelet factor 4 (PF4) is its 
ability to cause heparin induced thrombocytopenia due to the presence of antibodies 
reactive against the PF4/heparin complex (Chong et al., 1993). These reactive 
antibodies occur due to current or previous exposure to heparin. Essentially, heparin 
combines with endogenous PF4 to form an immune complex. This immune complex 
then binds to the FcγRII receptors on circulating platelets and induces platelet 
activation, promotes thrombin generation, and platelet aggregation. Activation of 
platelets induces the release of microparticles and ultimately leads to a reduction in 
the number of platelets, which is termed thrombocytopenia (Chong et al., 1993).  
In these studies, the ability of various heparins to promote a HIT response was 
examined in a platelet aggregation assay in which platelet rich plasma from normal 
donors was mixed with heparins and serum collected from known HIT positive 
patients. The aggregation response was used as an index for the potential to cause 
HIT. 
 All test agents, BMH, OMH and PMH produced comparable levels of HIT+ 
antibody mediated aggregation at the same concentrations (10 and 1 µg /ml). None of 
them showed Hit response at 0.1 µg /ml. 
In Vivo studies in non-human primates 
The main objective of this study was to evaluate the pharmacodynamics (PD) 
and pharmacokinetic (PK) profiles of various heparins in non-human primates. 
Bovine, ovine and porcine heparins were administered to primates intravenously (IV) 
at a dose of 500 µg/kg. The PK and PD profiles of BMH, OMH and PMH were 
determined using a variety of clotting and amidolytic assays (results shown in 
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Appendix). 
Concentration-response curves were made by supplementing BMH, OMH and 
PMH in pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml. 
Best-fit curves were made and the drug concentration in each monkey blood sample 
was determined by extrapolation using the measured percent inhibition of factor Xa 
and thrombin. The pharmacokinetic profiles of these agents were determined by non-
compartmental analysis using PKSolver® software. 
 Since heparins from various animal sources (i.e. pig, cow and sheep) have 
slight variability in molecular compositions, some differences in pharmacokinetics 
can be expected. This may be due to the binding to plasma proteins, in particular with 
Antithrombin and HCII. Furthermore, the vascular interactions of different heparins 
may also differ. 
Before discussing the PD and PK of these drugs, a few experimental 
limitations should be mentioned. Firstly, there is inter-animal variability (i.e. hepatic 
function, age, sex, and weight). Secondly, the results may also have been influenced 
by practical limitations on the number of blood samples that could be collected and by 
the number of primates that could be included in each treatment group.  
Individual heparins were injected intravenously, where they exerted rapid 
effects on both factor Xa and thrombin. All three drugs significantly prolonged the 
aPTT and TT clotting times with strong anticoagulant activity at 15 minutes post-
administration. The peak plasma concentrations also correlated with this time point. 
This peak anticoagulant activity was stronger for OMH and PMH than for BMH.  
 Administration of the various heparins at an IV dose of 0.5 mg/kg produced a 
significant inhibition of factor Xa and thrombin at 15 minutes. This effect gradually 
decreased until 120 minutes for all 3 agents. OMH and PMH had a significantly 
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stronger anti-Xa and anti-IIa effects compared to BMH up to 60 minutes post-
administration. However, all agents exhibited comparable anti-Xa and anti-IIa effects 
at 120 minutes. The plasma concentration-time courses followed the activity in the 
assay. Similar trends were observed in these assays. The only major difference was that 
at 120 minutes, the anti-Xa effect of OMH was somewhat lower than PMH and BMH.  
The pharmacokinetic parameters calculated from plasma concentration-time 
curves using the anti-Xa assay after IV administration of 0.5 mg/kg heparins to non-
human primates showed that, BMh exhibited a significantly longer half -life (t1/2) 
compared to PMH and OMH. However, no differences in area under the curve (AUC) 
were noted between each agent. Although BMH appeared to have a larger volume of 
distribution (Vd), no significant differences were noted between each agent. And more 
over, no differences in systemic clearance (Cl) were noted between each agent. The 
pharmacokinetic parameters calculated from plasma concentration-time curves using 
the anti-IIa assay showed the same trend except that BMH exhibited a significant larger 
volume of distribution (Vd) compared to PMH and OMH. 
Integrated discussion on the comparative structural and biological profiles of 
heparins obtained from different origins 
 Ever since the discovery of heparins, mammalian tissues have been used to 
isolate this anticoagulant. While the early discovery was in the dog liver (McLean et 
al.,1959), subsequently beef and pig lung and mucosa have been used to prepare 
heparins. The initial clinical batches of heparins were obtained from beef lung. 
However, due to BSE virus and other cattle borne viral contaminants, its use was 
stopped. This led to the widespread use of porcine mucosal heparins which are 
currently clinically used. Sheep heparin obtained from mucosal tissue was also 
developed and used in limited clinical indications. Because of the supply limitations 
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and quality issues with porcine heparin, the FDA has initiated plans to reintroduce 
bovine heparin. Sheep heparins also provide a major source of heparin and it is 
currently being developed (St. Ange et al., 2016). 
 The diversification of heparins is timely and will fill gaps in the use of 
heparins brought about by cultural and religious reasons. The development of bovine 
and ovine heparins will be widely accepted by countries with religious requirements.  
Ovine heparin will be of major interest for the Indian subcontinent with highly 
predominant Hindu and Muslim populations. Therefore, the availability of heparins 
from bovine and ovine sources will make this anticoagulation acceptable to 
individuals of all faiths. At the present time, a large amount of ovine mucosal tissue is 
wasted, which otherwise can be used for pharmaceutical purposes. This will be 
extremely valuable for managing supply and demand, and for providing alternate 
sources during emergency situations such as the contaminants crisis in 2008 (Liu et 
al., 2009). 
 The primary purpose of this thesis was to compare unfractionated BMH and 
OMH with the commonly used PMH. In these comparative studies, updated 
recommended profiling for the molecular and the structural attributes, biochemical 
properties, pharmacological neutralization profile, and interaction with HIT antibodies 
were investigated. In addition, the USP potencies of bovine and ovine heparins were 
cross referenced to equate the potency in the gravimetric amounts. The 
recommendations from regulatory agencies and USP were taken into considerations. 
 While the molecular weight profile of all the three heparins were comparable, 
the biochemical properties and pharmacological profiling of the BMH exhibited some 
differences from those of OMH and PMH. Notably, the BMH exhibited consistently 
lower potency on a gravimetric basis, which was in the range of 30-40% lower than 
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both the PMH and OMH. Thus, the results of this potency comparison suggest that to 
obtained equivalent USP activity, higher amounts of BMH will be needed. It is 
projected that potency adjusted BMH may exhibit comparable biochemical properties. 
The difference in potency may partly be due to antithrombin binding region which 
have been reported before (Casu et al., 1995). 
 In the current investigation, the BMH batches consistently showed lower USP 
potency, ranging from 120-150 U/mg, in contrast to OMH and PMH which were 
much higher. The primary reason for this lowered potency is most probably due to the 
prevalence of the AT binding region in BMH which has been reported before (Naggi 
et al., 2015). It is unlikely that inorganic ions such as sodium or chloride and the 
water of hydration contribute to the lowered potency observed in BMH, as all the 
heparin batches used in this study were stored in desiccated forms and were 
lyophilized prior to storage. Thus, it is unlikely that water of hydration contributes to 
the lowered potency observed with BMH. It should be stressed that the water of 
hydration content may differ in heparins and is influenced by storage conditions. In 
our studies, since the storage conditions were consistent for all heparins, it unlikely 
that this factor contributes to the potency calculation. 
 The studies reported on the in vivo pharmacokinetics in primates where the 
BMH, OMH and PMH were compared at a fixed gravimetric dosage of (0.5 mg/kg) 
IV, confirmed the lowered potency of BMH in both the anticoagulant and antiprotease 
assays. The proportionately decreased activities were a reflection of the composition 
of mucosal heparin, and the results were consistent with the observed in vitro studies. 
While some differences in the pharmacokinetic profiles were noted, the overall 
behavior of the unfractionated heparins was comparable. Based on this, it is projected 
that potency adjusted BMH at equivalent dosage may provide the same degree of 
99 
 
anticoagulation as the OMH and PMH.  
 The USFDA and the US pharmacopoeia have initiated plans to reintroduce 
bovine UFH for clinical use. At the same time, the Brazilian regulatory agency 
ANVISA has recently released a BMH monograph which recognizes the lowered 
potency of BMH and has included a potency limit of no less than 100 USP units per 
milligram for acceptance criterion (Brazilian Heparin Monograph, 2017). Most of the 
BMH preparations assayed using different methods provide widespread range assay 
dependent potency values. In the current USP assay this potency ranged of 90-140 
U/ml. The potency limit set forth by ANVISA is rather low and may compromise the 
quality of this anticoagulant. The USP is currently working on the release of its own 
monograph for bovine UFH and may likely follow the Brazilian monograph. It is also 
unclear whether bovine heparin will be considered as a separate drug or whether it 
will be considered as a biosimilar to PMH which will allow for interchangeability at a 
potency adjusted level. 
The minor differences noted in the microchemical structural between OMH 
and PMH did not influence the in vitro and in vivo profiles of these two 
anticoagulants, which were almost superimposable. Interestingly, the recent report in 
which BMH was compared with PMH for the anticoagulation during cardiovascular 
bypass surgery showed the comparability of these two agents in clinical settings 
(Gomes WJ. et al., 2016). 
 It is noteworthy to state that, the current studies reported in this thesis showed 
the biosimilarity and comparability of the unfractionated heparins obtained from the 
sheep heparin in comparison to porcine heparins. Despite slightly lower molecular 
weight and minor differences in degree of sulfation, the OMH was found to be 
comparable to the PMH in both the in vitro and in vivo studies. The results obtained 
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with both heparins were almost indistinguishable. It is projected that the ovine UFH 
will be comparable to porcine heparin in the various indications where the porcine 
heparin is used. 
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CHAPTER SIX 
SUMMARY 
         This dissertation addresses the biochemical and pharmacological profiles of 
various heparins derived from different animal sources. These studies explored 
their interactions with the coagulation system and their 
pharmacodynamic/pharmacokinetic behaviors. A summary of results from the 
major experimental protocols included in this dissertation is provided below. 
Physiochemical characterization 
1. BMH, OMH and PMH heparins exhibited comparable molecular weight (MW) 
profiles as determined by the size exclusion chromatography method. Each 
heparin exhibited specific elution profiles. The MWs profile of each heparin, in 
the range of 17.3 to 21.6 kDa, was cross referenced utilizing the narrow range 
calibrators (NRC) method using UV detector. 
2. These studies showed that BMH, OMH and PMH are degradable by heparinase-I 
to similar degrees resulting in oligosaccharides of much lower molecular weights. 
3. NMR analysis showed that the degree of sulfation of OMH was higher compared 
to that found in PMH and BMH. However, OMH shows a lower degree of 
acetylation compared to other heparins. 
In vitro studies 
1. The global anticoagulant and antiprotease effects of the BMH were consistently 
lower than PMH and OMH samples. Ovine and porcine heparins exhibited 
comparable anticoagulant and antiprotease activities.  
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2. The chromogenic antiprotease assays using Biomed kits showed that the USP 
potency of OMH and PMH were comparable and ranged from 180-210 U/mg. In 
contrast, the USP potency of BMH was much lower and ranged from 110-150 
U/mg. The anti-Xa / IIa ratio for all agents were comparable. 
3. In the purified AT supplemented system, the OMH and PMH preparations 
consistently showed lower IC50 values for both the thrombin and F-Xa inhibition 
in contrast to the BMH. 
4. Results from the neutralization studies showed that all heparins were consistently 
neutralized by protamine sulfate and heparinase-I to similar degrees. 
5. In the platelet based system studies, results demonstrated that there was no 
difference between the HIT responses in the heparins from different species.  
In Vivo studies in non-human primates 
1. The anti-Xa and anti-IIa effects of OMH and PMH were significantly stronger 
compared to BMH after IV administration. At equal gravimetric concentrations, 
the overall anticoagulant and antiprotease effects of OMH and PMH were 
comparable in the non-human primate model. 
2. The pharmacokinetic parameters in all studies were calculated from the 
concentrations derived from anti-Xa or anti-IIa activity using non-compartmental 
analysis. Bovine heparins showed a longer half -life (t1/2) compared to porcine and 
ovine heparins.  No major variations in AUC, Vd and CL parameters.  
Overall summary 
Although, some structural and functional differences are noted between the 
BMH, OMH and PMH, the results from this investigation clearly demonstrate the 
comparability of OMH and PMH. The BMH consistently exhibited lowered 
potency in all assays, which was also evident in the in vivo pharmacokinetic 
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studies. Potency adjusted BMH may exhibit comparable anticoagulant effects to 
OMH and PMH. Additional studies are warranted to validate this hypothesis.  
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CHAPTER SEVEN 
CONCLUSIONS 
Unfractionated heparin (UFH) is the first anticoagulant drug and has 
successfully used clinically for over 80 years. Heparin, and its analogues, are used 
during surgery, dialysis, and are often used to coat indwelling catheters and other 
devices where the vascular system is exposed. Most of the heparins used clinically are 
derived from porcine intestinal mucosa. However, heparins have also been 
manufactured from mammalians such as cows and sheep. Recently there have been 
attempts to generate bioengineered heparin. Currently there are some concerns about 
the shortage of the porcine heparins as they are widely used in the manufacturing of 
the low molecular weight heparins (LMWHs). Also, open-heart surgeries, 
hemodialysis and intervention cardiovascular procedures are usually carried out with 
anticoagulants and unfractionated heparins. Moreover, due to cultural and religious 
reasons in some countries, alternative sources of heparins are needed. The FDA and 
other regulatory agencies have considered re-sourcing of heparin for potential 
substitution of porcine heparin and are currently reviewing this matter. Numerous 
studies are ongoing to understand the structural-activity relationships of these various 
heparins. 
In this dissertation, heparins from different animal sources were studied to 
determine the extent of biosimilarity between them. For these investigations, thirty 
heparin batches were utilized. They included ten batches each BMH (21.6 kDa), OMH 
(17.3 kDa), and PMH (18.9 kDa). Their activities in biochemical and biological assays 
were compared to elucidate how their molecular 
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composition and structural attributes contribute to their pharmacological actions. 
 These studies have shown that BMH, OMH and PMH exhibit comparable 
molecular profiles. However, both 1H NMR and 13C NMR spectra have demonstrated 
that PMH and OMH have similar structure and composition while BMH is 
significantly different. These studies have also demonstrated that OMH and PMH 
have comparable anticoagulant and antiproteases activities. However, BMH exhibited 
somewhat lesser potencies compared to OMH and PMH in some of the functional 
assays. Potency adjustment for in vivo usage may be required to obtain comparable 
anticoagulant responses for the BMH. Neutralization studies have shown that all 
heparins exhibit comparable profiles. The same trend was noted in the HIT antibody 
interactions among heparins from different species. The anti-Xa and anti-IIa effects of 
OMH and PMH were significantly stronger compared to BMH after IV administration 
to non-human primates. Also, the pharmacokinetic parameters of all heparins were 
comparable. However, BMH showed significantly longer half-life (t1/2)   compared to 
other heparins. 
 Based on these studies, it is projected that potency adjusted BMH at 
equivalent dosage may provide the same degree of anticoagulant and antiprotease 
activities as OMH and PMH. Thus, while PMH and OMH may be interchangeable, 
BMH may require potency adjustment and thus exhibit a comparable profile to ovine 
and porcine heparins.  
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TABLE 1 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF 
PORCINE HEPARINS AS MEASURED BY THE NRC METHOD 
 
 
A- Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Batch 1 15879 19204 1.28 
Batch 2 15508 18918 1.27 
Batch 3 15399 19002 1.27 
Batch 4 15810 19252 1.27 
Batch 5 14599 18265 1.28 
Batch 6 14542 18061 1.26 
Batch 7 14402 18041 1.27 
Batch 8 16351 19572 1.23 
Batch 9 16120 19485 1.32 
Batch 10     16432 19310 1.31 
Mean ± SD 15504 (±757) 18911 (±581) 1.28 (±0.02) 
 
 
B- Detector/Method: RI /NRC 
 
Agent  Mn (Da) Mw (Da) Polydispersity 
Batch 1 16179 19793 1.31 
Batch 2 16263 19696 1.29 
Batch 3 16845 20305 1.31 
Batch 4 16992 20453 1.31 
Batch 5 15441 19085 1.29 
Batch 6 15287 18913 1.35 
Batch 7 15769 19433 1.29 
Batch 8 16868 20592 1.33 
Batch 9 17315 20638 1.32 
Batch 10     16578 20279 1.32 
Mean ± SD 16354 (±686) 19919 (±627) 1.31 (±0.02) 
 
The molecular weights of the porcine batches were determined by gel permeation 
chromatography. Mw is the weight average molecular weight, and Mn is the number average 
molecular weight. In Table A (UV), Mw ranged from 18 to 19.5 kDa. In Table B (RI), Mw 
ranged from 18.9 to 20.6 kDa. The calculated MWs were comparable between the UV and RI 
detectors NRC, narrow range calibrators; SD, standard deviation. 
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TABLE 2 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF 
BOVINE HEPARINS AS MEASURED BY THE NRC METHOD 
 
 
A- Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Batch 1 15929 20455 1.38 
Batch 2 17387 22024 1.37 
Batch 3 17470 22126 1.41 
Batch 4 17642 22348 1.42 
Batch 5 15979 20494 1.34 
Batch 6 17604 22115 1.32 
Batch 7 17312 22058 1.32 
Batch 8 18961 23242 1.33 
Batch 9 15934 20722 1.39 
Batch 10     15811 20753 1.37 
Mean ± SD 17203 (±845) 21634 (±954) 1.37 (±0.03) 
 
 
 
B- Detector/Method: RI /NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Batch 1 15901 20836 1.37 
Batch 2 17446 22593 1.38 
Batch 3 17461 22614 1.42 
Batch 4 17130 22486 1.37 
Batch 5 16448 21259 1.34 
Batch 6 17281 22432 1.34 
Batch 7 17803 22912 1.34 
Batch 8 16590 22104 1.32 
Batch 9 15899 21003 1.34 
Batch 10     16718 21783 1.35 
Mean ± SD 17868 (±662) 22002 (±741) 1.36 (±0.03) 
 
The molecular weights of the bovine batches were determined by gel permeation 
chromatography.  Mw is the weight average molecular weight, and Mn is the number average 
molecular weight. In Table A (UV), Mw ranged from 20.4 to 23.2 kDa. In Table B (RI), Mw 
ranged from 20.8 to 22.9 kDa. The calculated MWs were comparable between the UV and RI 
detectors. NRC, narrow range calibrators; SD, standard deviation. 
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TABLE 3 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF 
OVINE HEPARINS AS MEASURED BY THE NRC METHOD 
 
 
A- Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Batch 1 12423 17423 1.21 
Batch 2 12451 17533 1.22 
Batch 3 12556 17645 1.23 
Batch 4 12500 17699 1.22 
Batch 5 14056 18862 1.25 
Batch 6 13931 18450 1.24 
Batch 7 12330 16244 1.25 
Batch 8 11768 15601 1.20 
Batch 9 11714 16324 1.21 
Batch 10     12661 17324 1.18 
Mean ± SD 12639 (±781) 17311 (±1004) 1.22 (±0.02) 
 
 
 
B- Detector/Method: RI /NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Batch 1 12865 17649 1.22 
Batch 2 12761 17585 1.21 
Batch 3 12447 17399 1.21 
Batch 4 13330 18199 1.20 
Batch 5 14438 19385 1.24 
Batch 6 14424 19272 1.24 
Batch 7 12025 16125 1.23 
Batch 8 11796 15587 1.22 
Batch 9 11961 16085 1.19 
Batch 10     12889 17400 1.22 
Mean ± SD 12894 (±941) 17469 (±1281) 1.22 (±0.02) 
 
The molecular weights of the ovine batches were determined by gel permeation chromatography.  
Mw is the weight average molecular weight, and Mn is the number average molecular weight.  In 
Table A (UV), Mw ranged from 15.6 to 18.8 kDa. In Table B, Mw ranged from 15.6 to 19.4 
kDa. The calculated MWs were comparable between the UV and RI detectors. NRC, narrow 
range calibrators; SD, standard deviation. 
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TABLE 4 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS HEPARIN POOLS 
AS MEASURED BY THE NRC METHOD 
 
 
A- Detector/Method: UV (205 nm)/NRC 
 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Porcine pool 15544 (±93) 18601 (±534) 1.26 (±0.08) 
Bovine pool 17262 (+-366) 21974 (±387) 1.35 (±0.07) 
Ovine pool 13387 (±279) 18187 (±265) 1.21 (±0.08) 
 
 
 
B- Detector/Method: RI /NRC 
 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Porcine pool 16794 (±166) 19724 (±458) 1.33 (±0.07) 
Bovine pool 18286 (+-262) 23226 (±313) 1.31 (±0.09) 
Ovine pool 14297 (±199) 18803 (±155) 1.26 (±0.06) 
 
All results represent the mean (±) standard deviation (n=2). The molecular weights of different 
heparin pools were determined by gel permeation chromatography. Mw is the weight average 
molecular weight, and Mn is the number average molecular weight. The calculated MWs were 
comparable between the UV and RI detectors. NRC, narrow range calibrators. 
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TABLE 5 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS HEPARIN POOLS 
PRE AND POST HEPARINASE DIGESTION AS MEASURED BY THE NRC METHOD 
 
 
A- Detector/Method: UV (205 nm)/NRC 
 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Pre-Porcine Pool 15159 (±218) 18247 (±208) 1.24 (±0.08) 
Pre-Bovine Pool 16389 (±221) 21986 (±151) 1.31 (±0.09) 
Pre-Ovine Pool 13430 (±248) 16654 (±234) 1.21 (±0.6) 
Post-Porcine 3115 (±92) 3147 (±196) 1.03 (±0.07) 
Post-Bovine Pool 3130 (±197) 3086 (±123) 1.05 (±0.5) 
Post-Ovine Pool 2994 (±132) 3312 (±189) 1.03 (±0.6) 
 
 
B- Detector/Method: RI /NRC 
 
 
Agent Mn (Da) Mw (Da) Polydispersity 
Pre-Porcine Pool 16156 (±149) 19646 (±208) 1.32 (±0.05) 
Pre-Bovine Pool 17154 (±219) 22282 (±258) 1.23 (±0.07) 
Pre-Ovine Pool 15003 (±147) 18088 (±142) 1.28 (±0.6) 
Post-Porcine 3152 (±87) 3223 (±159) 1.09 (±0.03) 
Post-Bovine Pool 3754 (±217) 3361 (±88) 1.05 (±0.2) 
Post-Ovine Pool 3209 (±140) 3427 (±197) 1.06 (±0.3) 
 
All results represent the mean (±) standard deviation (n=2). The molecular weights of different 
heparins pools pre and post heparinase digestion were determined by gel permeation 
chromatography. Mw is the weight average molecular weight, and Mn is the number average 
molecular weight.  The calculated MWs were comparable between the UV and RI detectors. 
NRC, narrow range calibrators. 
 
 
 
 
 
 
 
 
112 
 
TABLE 6 
 
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN POOLS IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY  
 
 
 
Concentration Porcine Pool Bovine Pool Ovine Pool 
 (µg/ml) Time (sec) Time (sec) Time (sec) 
10 300 (±0.0) 300 (±0.0) 300 (±0.0) 
5 300 (±0.0) 207 (±4) 300 (±0.0) 
2.5 108 (±2) 78 (±1.2) 137.5 (±3.5) 
1.25 60 (±2) 45.9 (±1.4) 65.2 (±2.7) 
0.625 32.5 (±1) 29 (±0.75) 38.8 (±0.2) 
0 28.6 (±0.6) 28.6 (±0.6) 28.6 (±0.6) 
 
 
 
TABLE 7 
 
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN BATCHES IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY 
 
 
Concentration Porcine Batches Bovine Batches Ovine Batches 
 (µg/ml) Time (sec) Time (sec) Time (sec) 
10 300 (±0.0) 300 (±0.0) 300 (±0.0) 
5 300 (± 0) 189.9 (±17) 300 (± 0) 
2.5 74.2 (±11) 76.5 (±4.5) 66 (±6.3) 
1.25 43 (±4.5) 45.8 (±2.6) 43 (±4.7) 
0.625 32.5 (±2.4) 34.7 (±2.7) 32.9 (±3.2) 
0 28.2 (±0.0)  29 (±0.0)  27.6 (±0.0)  
 
All results represent the mean (±) standard deviation (n=2-10). Comparative anticoagulant 
effects in blood bank plasma (BBP) as measured by the APTT assay. Heparin pools (Table 6) 
and heparin means (Table 7). All agents were supplemented in the BBP over a concentration 
range of 0 to 10 µg/ml. Ovine and porcine heparins exhibited significant (*p <0.05) 
anticoagulant effects at the 5 µg/ml concentration compared to bovine ones. Additionally, ovine 
and porcine heparin pools (Table 6) produced longer clotting times compared to bovine heparin 
pool at all concentrations. 
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TABLE 8 
 
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN POOLS IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY TT ASSAY 
 
 
 
Concentration Porcine Pool Bovine Pool Ovine Pool 
 (µg/ml) Time (sec) Time (sec) Time (sec) 
10 300 (±0.0) 300 (±0.0) 300 (±0.0) 
5 300 (±0.0) 300 (±0.0) 300 (±0.0) 
2.5 300 (±0.0) 300 (±0.0) 300 (±0.0) 
1.25 300 (±0.0) 82 (±5) 300 (±0.0) 
0.625 18.6 (±0.9) 13 (±1.1) 17.7 (±1.2) 
0 9.4 (±0.2) 9.4 (±0.2) 9.4 (±0.2) 
 
 
 
TABLE 9 
 
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN BATCHES IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY TT ASSAY 
 
 
 
Concentration 
 
Porcine Batches 
 
Bovine Batches 
 
Ovine Batches 
 (µg/ml)   Time (sec)   Time (sec)   Time (sec) 
10   300 (±0.0)   300 (±0.0)   300 (±0.0) 
5 
 
300 (±0.0) 
 
300 (±0.0) 
 
300 (±0.0) 
2.5 
 
300 (±0.0) 
 
300 (±0.0) 
 
300 (±0.0) 
1.25 
 
300 (±0.0) 
 
45.2 (±6.6) 
 
300 (±0.0) 
0.625 
 
19.45 (±2.2) 
 
18.9 (±1.5) 
 
25.1 (±2.3) 
0   14.5 (±0.0)   16.2 (±0.0)   12.3 (±0.0) 
 
All results represent the mean (±) standard deviation (n=2-10). Comparative anticoagulant 
effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. Heparin pools 
(Table 8) and heparin means (Table 9). All agents were supplemented in the BBP over a 
concentration range of 0 to 10 µg/ml. Ovine and porcine heparins exhibited significant (p <0.05) 
anticoagulant effects at the 1.25 µg/ml concentration, while bovine heparins exhibited significant 
(p <0.001) anticoagulant effects at 2.5 µg/ml concentration. 
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TABLE 10 
 
THE INHIBITION OF FACTOR XA BY VARIOUS HEPARIN POOLS IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY 
 
 
 
 
Concentration Porcine Pool Bovine Pool Ovine Pool 
 (µg/ml) % Inhibition % Inhibition % Inhibition 
10 93.7 (±1.2) 89.2 (±0.4) 97 (±1.5) 
5 87 (±1) 72.3 (±2.6) 91 (±1.1) 
2.5 64.5 (±1) 50.4 (±1) 71.2 (±0.3) 
1.25 33 (±0.1) 30.8 (±0.9) 45.7 (±1.1) 
0.625 19.3 (±0.4) 17 (±0.6) 20.4 (±0.8) 
0 0 (±0.0) 0 (±0.0) 0 (±0.0) 
 
 
 
TABLE 11 
 
THE INHIBITION OF FACTOR XA BY VARIOUS HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY 
 
 
 
Concentration 
 
Porcine Batches 
 
Bovine Batches 
 
Ovine Batches 
 (µg/ml)   % Inhibition   % Inhibition   % Inhibition 
10   92.5 (±1.4)   84.1 (±1)   95.5 (±1) 
5 
 
83.1 (±2.7) 
 
66.7 (±5.3) 
 
88.4 (±3.4) 
2.5 
 
55.6 (±5.3) 
 
48.9 (±4.6) 
 
65.3 (±3.1) 
1.25 
 
29.7 (±3.3) 
 
28.5 (±3.6) 
 
33.5 (±2.2) 
0.625 
 
17.9 (±1.4) 
 
13.9 (±2.2) 
 
15.3 (±2.4) 
0   0 (±0.0)   0 (±0.0)   0 (±0.0) 
 
All results represent the mean (±) standard deviation (n=2-10). The inhibition of factor Xa in 
blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. Heparin pools (Table 
10) and heparin means (Table 11).  All agents were supplemented in the BBP over a 
concentration range of 0 to 10 µg/ml. Porcine and ovine heparins showed comparable activities 
and both were more potent inhibitors of factor Xa than bovine heparins (p <0.01). 
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TABLE 12 
 
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS HEPARIN POOLS IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA 
ASSAY 
 
 
 
Concentration Porcine Pool Bovine Pool Ovine Pool 
 (µg/ml) % Inhibition % Inhibition % Inhibition 
10 84.2 (±0.7) 76 (±1.3) 89 (±0.5) 
5 77.4 (±1.5) 65.6 (±2.3) 84 (±0.95) 
2.5 68.4 (±0.1) 58 (±1.0) 73 (±0.5) 
1.25 54.3 (±1.4) 42.3 (±0.5) 57.5 (±0.5) 
0.625 47.5 (±0.7) 32.2 (±0.7) 48.7 (±0.8) 
0 0 (±0.0) 0 (±0.0) 0 (±0.0) 
 
 
 
TABLE 13 
 
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS HEPARIN BATCHES IN 
BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA 
ASSAY 
 
 
 
Concentration 
 
Porcine Batches 
 
Bovine Batches 
 
Ovine Batches 
 (µg/ml)   % Inhibition   % Inhibition   % Inhibition 
10   84.6 (±1.56)   80.7 (±2.2)   88.1 (±2.9) 
5 
 
80.8 (±4) 
 
 76.2 (±3.4) 
 
81.1 (±3.3) 
2.5 
 
69.9 (±4.3) 
 
54.5 (±2.9) 
 
70 (±3.8) 
1.25 
 
54.7 (±3.2) 
 
39.7 (±3.5) 
 
57.5 (±3) 
0.625 
 
48.1 (±4.7) 
 
23.6 (±3.4) 
 
51.4 (±3.2) 
0   0 (±0.0)   0 (±0.0)   0 (±0.0) 
 
All results represent the mean (±) standard deviation (n=2-10). The inhibition of thrombin 
(Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. Heparin 
pools (Table 12) and heparin means (Table 13).  All agents were supplemented in the BBP over a 
concentration range of 0 to 10 µg/ml. Porcine and ovine pools showed comparable activities and 
both were more potent inhibitors of thrombin (Factor IIa) than bovine heparins (p <0.03). 
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TABLE 14 
 
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN POOLS AS MEASURED BY 
THE CHROMOGENIC ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED 
KITS 
 
 
 
Agents Xa (U/mg) IIa (U/mg) Xa/IIa Ratio 
Porcine Pool 190 (±1.4) 186 (±1.4) 1.02 
Bovine Pool 135 (±2.1) 131 (±1.3) 1.03 
Ovine Pool 197 (±2.8) 200 (±1.2) 0.99 
 
 
 
TABLE 15 
 
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN BATCHES AS MEASURED 
BY THE CHROMOGENIC ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED 
KITS 
 
 
 
Agents Xa (U/mg) IIa (U/mg) Xa/IIa Ratio 
Porcine Batches 189.7 (±4.2) 183.9 (±5.3) 1.03 
Bovine Batches 137.8 (±8.4) 139.8 (±11.1) 0.99 
Ovine Batches 191.6 (±6.4) 187.6 (±7.1) 1.01 
 
All results represent the mean (±) standard deviation (n=2-10). Comparative USP potencies as 
measured by the chromogenic anti-Xa and Anti-IIa assays (Hyphen Kits). Heparin pools (Table 
14) and heparin means (Table 15). The USP potency of porcine and ovine heparins were 
comparable and ranged from 184-192 U/mg. In contrast, the USP potency of the bovine heparins 
was much lower and ranged from 138-140 U/mg. However, the anti-Xa / IIa ratio of all heparins 
were comparable.  
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TABLE 16 
 
POTENCY COMARISON FOR VARIOUS HEPARIN POOLS WHEN SUPPLEMENTED IN 
PURIFIED AT AS MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA 
ASSAYS 
 
 
 
Drug 
Anti-Xa Anti-IIa 
IC50 (µg/ml) IC50 (µg/ml) 
Porcine Pools  2.72 (±0.04) 0.32 (±0.02) 
Bovine Pools 3.70 (±0.07) 0.50 (±0.01) 
Ovine Pools 2.26 (±0.06) 0.28 (±0.01) 
 
 
 
TABLE 17 
 
POTENCY COMARISON FOR VARIOUS HEPARIN BATCHES WHEN SUPPLEMENTED 
IN PURIFIED AT AS MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA 
ASSAYS 
 
 
 
Drug 
Anti-Xa Anti-IIa 
IC50 (µg/ml) IC50 (µg/ml) 
Porcine Batches  2.52 (±0.26) 0.29 (±0.02) 
Bovine Batches 3.67 (±0.4) 0.39 (±0.07) 
Ovine Batches 2.08 (±0.29) 0.25 (±0.02) 
 
All results represent the mean IC50 values (±) standard deviation (n= 2-10). Xa, factor Xa; IIa 
thrombin; AT, antithrombin.  
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TABLE 18 
 
 NEUTRALIZATION PROFILE OF PORCINE HEPARIN POOL USING PROTAMINE 
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE 
ASSAYS 
 
 
 
 
Porcine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 94 (±1.0) 86 (±0.0) 
5 271 (±2.8) 300 (±0.0) 83.3 (±0.5) 84.5 (±0.7) 
2.5 166 (±4.2) 300 (±0.0) 63.9 (±0.6) 75 (±0.0) 
1.25 79.9 (±1.4) 300 (±0.0) 35.5 (±1.7) 64.5 (±4.9) 
0.62 45 (±1.7) 18.5 (±0.7) 14.1 (±0.8) 46.7 (±0.9) 
0 33 (±0.0) 11.1 (±0.4) 0.0 (±0.0) 0.0 (±0.0) 
     
 
Porcine Pool + Protamine Sulfate 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 176.5 (±6.2) 300 (±0.0) 48.1 (±2.3) 90.4 (±1.5) 
5 36.5 (±0.4) 13.3 (±0.6) 0.9 (±0.3) 6.9 (±0.9) 
2.5 36 (±0.4) 13 (±0.4) 1.8 (±0.1) 6.7 (±0.6) 
1.25 38.1 (±0.2) 13.3 (±0.2) 2.4 (±0.1) 6.6 (±0.5) 
0.62 34.9 (±0.6) 13 (±0.3) 2.4 (±0.5) 7.3 (±0.2) 
0 34.2 (±0.0) 10 (±0.1) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time. 
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TABLE 19 
 
 NEUTRALIZATION PROFILE OF BOVINE HEPARIN POOL USING PROTAMINE 
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE 
ASSAYS 
 
 
 
 
Bovine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 83.3 (±1.5) 79 (±1.4) 
5 192.5 (±3.5) 300 (±0.0) 64 (±2.1) 73 (±1.4) 
2.5 140 (±1.5) 300 (±0.0) 40.3 (±1.3) 66.5 (±2.1) 
1.25 59.9 (±1.1) 20 (±1.4) 18.9 (±0.8) 52.9 (±1.6) 
0.62 37 (±1.2) 15.7 (±0.7) 4.6 (±1.8) 36.5 (±0.7) 
0 33 (±0.0) 11.1 (±0.4) 0.0 (±0.0) 0.0 (±0.0) 
     
 
Bovine Pool + Protamine Sulfate 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 94 (±1.8) 300 (±0.0) 24.1 (±2.2) 60.7 (±0.2) 
5 37 (±0.7) 13 (±0.3) 0.9 (±0.1) 4.3 (±0.8) 
2.5 37.8 (±0.1) 12.6 (±0.4) 1 (±0.2) 5.4 (±0.7 
1.25 37.3 (±0.6) 11.9 (±0.3) 0.9 (±0.1) 7.0 (±1.1) 
0.62 34.1 (±1.2) 11.1 (±0.4) 0.8 (±0.1) 8.2 (±0.6) 
0 34.2 (±0.0) 10 (±0.1) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time. 
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TABLE 20 
 
 NEUTRALIZATION PROFILE OF OVINE HEPARIN POOL USING PROTAMINE 
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE 
ASSAYS 
 
 
 
 
Ovine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 95.4 (±0.8) 89 (±1.4) 
5 300 (±0.0) 300 (±0.0) 89.9 (±0.3) 87 (±1.4) 
2.5 173 (±1.4) 300 (±0.0) 74.6 (±1.0) 77 (±1.3) 
1.25 78.2 (±2.4) 300 (±0.0) 49.8 (±2.1) 70.5 (±2.1) 
0.62 48.6 (±2.3) 18.7 (±1.6) 23.6 (±1.3) 44 (±7.1) 
0 33 (±0.0) 11.1 (±0.4) 0.0 (±0.0) 0.0 (±0.0) 
     
     
 
Ovine Pool + Protamine Sulfate 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 74.9 (±1.3) 90.6 (±0.6) 
5 37.1 (±1.6) 12.1 (±1.0) 0.7 (±0.3) 7.4 (±0.1) 
2.5 35.2 (±0.4) 12.3 (±0.4) 0.5 (±0.1) 7.5 (±0.1) 
1.25 35.3 (±0.4) 11.1 (±0.4) 1.0 (±0.4) 8.4 (±0.4) 
0.62 36.1 (±0.6) 13.4 (±0.7) 1.3 (±0.1) 9.3 (±0.8) 
0 34.2 (±0.0) 10 (±0.1) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time. 
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TABLE 21 
 
 NEUTRALIZATION PROFILE OF PORCINE HEPARIN POOL USING HEPARINASE-1 AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS 
 
 
 
 
Porcine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 92.1 (±0.3) 84.3 (±1.1) 
5 283.5 (±7.8) 300 (±0.0) 82.7 (±0.4) 78.5 (±3.7) 
2.5 103 (±2.8) 300 (±0.0) 63.7 (±1.9) 66.7 (±2.4) 
1.25 54 (±2.6) 300 (±0.0) 39.8 (±2.1) 53.6 (±2.9) 
0.62 38.1 (±1.3) 19.7 (±0.9) 21.2 (±1.1) 44.9 (±2.7) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
  
 
   
 
Porcine Pool + Heparinase-1 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 37 (±1.4) 15 (±1.8) 10.3 (±0.7) 15.9 (±0.8) 
5 34.8 (±1.8) 18.2 (±1.0) 6.8 (±0.4) 13.8 (±0.6) 
2.5 34.3 (±2.2) 15.8 (±0.6) 2.8 (±1.1) 7.4 (±0.6) 
1.25 32.8 (±1.1) 15.9 (±1.5) 2.0 (±1.4) 4.4 (±0.9) 
0.62 32.9 (±1.6) 14.1 (±1.7) 0.8 (±0.1) 3.0 (±0.6) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time. 
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TABLE 22 
 
 NEUTRALIZATION PROFILE OF BOVINE HEPARIN POOL USING HEPARINASE-1 AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS 
 
 
 
 
Bovine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 84.9 (±0.3) 78.9 (±0.4) 
5 177.5 (±4.9) 300 (±0.0) 66.1 (±1.8) 67.2 (±2.6) 
2.5 75.5 (±0.8) 300 (±0.0) 45.5 (±4.7) 57.2 (±1.2) 
1.25 47.3 (±2.5) 18.1 (±0.6) 23.8 (±2.1) 41.9 (±1.6) 
0.62 37.1 (±1.3) 14.6 (±2.3) 12.6 (±1.2) 33.5 (±0.8) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
     
 
Bovine Pool + Heparinase-1 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 39.5 (±0.1) 17.9 (±1.1) 11.3 (±0.6) 15.3 (±0.5) 
5 35.8 (±1.5) 15.7 (±1.0) 7.9 (±0.1) 12.9 (±1.1) 
2.5 34.9 (±3.0) 15.4 (±0.5) 4.4 (±0.3) 8.9 (±1.2) 
1.25 33.9 (±1.6) 15.5 (±1.6) 2.4 (±0.2) 4.7 (±0.8) 
0.62 34.2 (±3.5) 15.6 (±2.4) 0.7 (±0.1) 3.1 (±0.6) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time. 
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TABLE 23 
 
 NEUTRALIZATION PROFILE OF OVINE HEPARIN POOL USING HEPARINASE-1 AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS 
 
 
 
 
Ovine Pool + Saline 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 300 (±0.0) 300 (±0.0) 94 (±0.7) 88.8 (±0.3) 
5 300 (±0.0) 300 (±0.0) 86.9 (±0.9) 85.4 (±0.8) 
2.5 125 (±1.4) 300 (±0.0) 68.2 (±1.1) 73.1 (±1.3) 
1.25 62.5 (±3.5) 300 (±0.0) 43.0 (±1.3) 56.5 (±0.7) 
0.62 41.1 (±1.3) 22.7 (±2.3) 23.7 (±1.2) 47.7 (±2.4) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
     
 
Ovine Pool + Heparinase-1 
 
Concentration aPTT TT Anti-Xa Anti-IIa 
(µg/ml) (Sec) (Sec) (% Inhibition) (% Inhibition) 
10 38.1 (±1.2) 14.9 (±2.3) 13.8 (±0.1) 13.6 (±1.9) 
5 35.5 (±2.1) 14.1 (±1.8) 7.6 (±1.5) 11.2 (±0.6) 
2.5 33.6 (±1.3) 14.5 (±3.1) 3.8 (±0.1) 9.5 (±0.6) 
1.25 33.3 (±1.1) 15.1 (±3.6) 4.9 (±1.7) 5.3 (±1.1) 
0.62 32.4 (±1.0) 16.3 (±0.3) 0.9 (±0.1) 4.0 (±1.1) 
0 32.1 (±0.5) 13.7 (±0.6) 0.0 (±0.0) 0.0 (±0.0) 
 
All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial 
thromboplastin time; TT, thrombin time.
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TABLE 24 
 
THE EFFECT OF VARIOUS HEPARIN POOLS ON HIT POSITIVE ANTIBODY MEDIATED PLATELET AGGREGATION 
 
 
 
Agent 
FC=10 µg/ml FC=1 µg/ml FC=0.1 µg/ml 
% Aggregation Slope % Aggregation Slope % Aggregation Slope 
Saline 5 (±1.2) 1.2 (±0.4) 5 (±1.2) 1.2 (±0.4) 5 (±1.2) 1.2 (±0.4) 
AA 81 (±5) 42.8 (±4.1) 81 (±5) 42.8 (±4.1) 81 (±5) 42.8 (±4.1) 
Porcine pool 65.4 (±3) 16 (±2.9) 72.4 (±8.6) 14.8 (±6.9) 6.2 (±2.4) 1.2 (±0.4) 
Bovine Pool 56.2 (±7) 12.4 (±2.4) 71.4 (±5.4) 13 (±6.7) 4.4 (±2.3) 1(±0.0) 
Ovine Pool 67.2 (±10.2) 18.8 (±6.9) 74.6 (±7.4) 18.4 (±6.4) 5 (±2.3) 1(±0.0) 
 
All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 25 
 
THE EFFECT OF VARIOUS HEPARIN POOLS PRE AND POST HEPARINASE-1 DIGESTION ON HIT POSITIVE ANTIBODY 
PLATELET AGGREGATION 
 
 
Heparin Pools +Saline 
 
Agent 
FC=10 µg/ml FC=1 µg/ml FC=0.1 µg/ml 
% Aggregation Slope % Aggregation Slope % Aggregation Slope 
Saline 3.2 (±1.8) 1.0 (±0.0) 3.2 (±1.8) 1.0 (±0.0) 3.2 (±1.8) 1.0 (±0.0) 
AA 77 (±5.8) 46.2 (±3.6) 77 (±5.8) 46.2 (±3.6) 77 (±5.8) 46.2 (±3.6) 
Porcine pool 76.6 (±7.9) 20.5 (±3.0) 59.8 (±11.7) 15.4 (±2.3) 3.3 (±0.8) 2 (±1.0) 
Bovine Pool 71.1 (±5.2) 23.6 (±3.3) 72.4 (±6.6) 20.4 (±2.3) 3.6 (±0.8) 2.2(±0.8) 
Ovine Pool 60.6 (±9.1) 16.5 (±1.7) 64.8 (±4.9) 22.4 (±4.0) 4.8 (±1.1) 1.8(±0.8) 
  
Heparin Pools + Heparinase-1 
 
Agent 
FC=10 µg/ml FC=1 µg/ml FC=0.1 µg/ml 
% Aggregation Slope % Aggregation Slope % Aggregation Slope 
Saline 3.2 (±1.8) 1.0 (±0.0) 3.2 (±1.8) 1.0 (±0.0) 3.2 (±1.8) 1.0 (±0.0) 
AA 77 (±5.8) 46.2 (±3.6) 77 (±5.8) 46.2 (±3.6) 77 (±5.8) 46.2 (±3.6) 
Porcine pool 4.8 (±1.5) 1.8 (±0.8) 4 (±1.0) 2 (±1.0) 4.2 (±1.1) 1.4 (±0.5) 
Bovine Pool 6.8 (±1.3) 1.8 (±0.8) 4.2 (±2.2) 2 (±1.0) 2.4 (±0.5) 1.8(±0.8) 
Ovine Pool 5.4 (±2.4) 2.0 (±0.9) 4.8 (±2.2) 2.6 (±1.1) 3.8 (±0.8) 1.4(±0.5) 
 
All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia. 
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TABLE 26 
 
COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF VARIOUS HEPARIN POOLS AS DETERMINED BY 
VARIOUS ANTIPROTEASE AND ANTICOAGULANT ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES 
 
 
 
Drug Time  Anti-Xa Anti-IIa aPTT TT 
0.5 mg/kg IV (Minutes) (% Inhibition) (% Inhibition) (Seconds) (Seconds) 
 
0 0.0 (±0.0)  0.0 (±0.0) 24.7 (±1.8) 21.6 (±1.6) 
 
15 88.5 (±5.5) 89.5 (±3.4) 38.8 (±1.0) 300 (±0.0) 
Porcine Pool 30 85.5 (±6.5) 77.0 (±3.9) 35.2 (±3.7) 300 (±0.0) 
 
60 73.0 (±9.8) 69.8 (±2.5) 30.9 (±2.8) 300 (±0.0) 
  120 4.7.0 (±7.2) 52.0 (±3.8) 25.7 (±1.8) 22.7 (±1.4) 
 
0 0.0 (±0.0) 0.0 (±0.0) 24.8 (±1.0) 18.1 (±3.1) 
 
15 79.3 (±6.3) 80.5 (±2.6) 33.6 (±2.9) 300 (±0.0) 
Bovine Pool 30 64.8 (±8.8) 68.5 (±5.8) 31.5 (±0.9) 300 (±0.0) 
 
60 52.5 (±6.1) 51.5 (±4.2) 28.2 (±1.4) 27.0 (±1.8) 
  120 42.5 (±4.4) 41.3 (±5.7) 26.2 (±1.4) 19.9 (±2.1) 
 
0 0.0 (±0.0) 0.0 (±0.0) 24.4 (±1.6) 19.7 (±2.1) 
 
15 90.5 (±7.1) 92.3 (±2.5) 39.8 (±2.3) 300 (±0.0) 
Ovine Pool 30 87.3 (±7.2) 81.0 (±2.9) 36.4 (±1.5) 300 (±0.0) 
 
60 78.3 (±9.1) 70.8 (±4.3) 29.9 (±1.9) 300 (±0.0) 
  120 49.8 (±7.6) 57.0 (±6.1) 25.8 (±2.2) 22.8 (±1.4) 
 
All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin; aPTT, activated partial thromboplastin time; 
TT, thrombin time. 
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TABLE 27 
 
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS HEPARIN POOLS AS DETERMINED BY 
VARIOUS ANTIPROTEASE ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES 
 
 
 
 
Drug Time  Anti-Xa Anti-IIa 
0.5 mg/kg IV (Minutes) Concentration (U/ml) Concentration (U/ml) 
 
0 0.0 (±0.0) 0.0 (±0.0) 
 
15 2.2 (±0.1) 1.9 (±0.3) 
Porcine Pool 30 1.5 (±0.3) 1.7 (±0.3) 
 
60 1.2 (±0.3) 1.3 (±0.3) 
  120 0.6 (±0.3) 0.6 (±0.3) 
 
0 0.0 (±0.0) 0.0 (±0.0) 
 
15 1.5 (±0.1) 1.2 (±0.2) 
Bovine Pool 30 1.0 (±0.2) 0.8 (±0.1) 
 
60 0.8 (±0.2) 0.3 (±0.2) 
  120 0.6 (±0.2) 0.2 (±0.1) 
 
0 0.0 (±0.0) 0.0 (±0.0) 
 
15 2.3 (±0.1) 2.2 (±0.1) 
Ovine Pool 30 1.7 (±0.1) 1.7 (±0.2) 
 
60 1.0 (±0.2) 1.0 (±0.2) 
  120 0.4 (±0.1) 0.4 (±0.1) 
 
All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin. 
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TABLE 28 
 
ESTAMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION TIME 
CURVES AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES 
 
 
U/ml 
 
Test Drug Half-life; mins AUC; (U*mins)/ml Vd; ml/kg Cl; ml/kg/mins 
Anti-Xa Porcine pool 60 (±8) 210 (±11) 39 (±6) 0.5 (±0.1) 
IV 500 μg/kg 
Bovine pool 96 (±13) 185 (±12) 48 (±5) 0.4 (±0.1) 
  
Ovine pool 40 (±6) 171 (±7) 34 (±4) 0.6 (±0.1) 
Anti-IIa 
Porcine pool 58 (±8.4) 205 (±14) 38 (±6) 0.5 (±0.1) 
IV 500 μg/kg 
Bovine pool 105 (±14) 163 (±12) 60 (±8) 0.4 (±0.1) 
  
Ovine pool 40 (±3) 168 (±9) 34 (±6) 0.6 (±0.1) 
 
 
All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa, 
factor Xa; IIa, thrombin. 
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Table 29 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL PORCINE HEPARIN BATCHES IN BLOOD 
BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 300 300 300 300 300 300 300 300 300 300 
2.5 70 68 59 74 65 59.7 61.2 57.7 75.7 71.6 
1.25 51 46 46 49 36 38.5 39 38.8 43.7 42.3 
0.625 32.8 36 33 41 30 31.1 30.6 30.5 32.3 31.9 
0 28 28 28 28 28 28 28 28 28 28 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All porcine heparin batches 
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 30 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL BOVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY APTT ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 183 169 203 170 218 210 207 182 175 182 
2.5 74.9 70.5 79.2 73.7 81.7 85.9 75.7 73.4 72.3 78 
1.25 45.7 44.7 44.5 43.5 45.2 46.5 44.2 43.2 49 52 
0.625 35.5 39 29.7 34 35.5 33.5 33 33.2 35 39 
0 29 29 29 29 29 29 29 29 29 29 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All bovine heparin batches 
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 31 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL OVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY APTT ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 300 300 300 300 300 300 300 300 300 300 
2.5 80.9 77.5 85.5 96.4 62.4 66.9 68.3 66.5 78.3 59.6 
1.25 46.9 44.4 48.7 51.4 39.2 41.8 39.4 38.4 42.8 37.4 
0.625 34.3 34.2 35.9 36.6 30.7 31.6 30.3 30.8 31.2 29.6 
0 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All ovine heparin batches 
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 32 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL PORCINE HEPARIN BATCHES IN BLOOD 
BANK PLASMA (BBP) AS MEASURED BY TT ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 300 300 300 300 300 300 300 300 300 300 
2.5 300 300 300 300 300 300 300 300 300 300 
1.25 300 300 300 300 300 300 300 300 300 300 
0.625 23.7 21 24.3 24.6 27.8 27.3 22.4 26.8 25.8 28.4 
0 12.3 12.3 12.3 12.3 12.3 12.3 12.3 12.3 12.3 12.3 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All porcine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 33 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL BOVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY TT ASSAY 
 
Concentratio
n 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 300 300 300 300 300 300 300 300 300 300 
2.5 300 300 300 300 300 300 300 300 300 300 
1.25 36 48 41 38 57 42 53 49 49 39 
0.625 16 18 18.4 18.4 17.5 19.6 19.4 20.5 21.6 19.8 
0 15.2 15.2 15.2 15.2 15.2 15.2 15.2 15.2 15.2 15.2 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All bovine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 34 
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL OVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY TT ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
Time 
(sec) 
10 300 300 300 300 300 300 300 300 300 300 
5 300 300 300 300 300 300 300 300 300 300 
2.5 300 300 300 300 300 300 300 300 300 300 
1.25 300 300 300 300 300 300 300 300 300 300 
0.625 20 17 22 17.9 19.6 23 19.6 21 17.5 16 
0 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5 
 
Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All ovine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
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Table 35 
THE INHIBITION OF FACTOR XA BY VARIOUS PORCINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP) 
AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 92 91 92 94 91 93 94 95 92 91 
5 82 84 87 80 82 84 78 83 87 84 
2.5 59 64 54 51 52 57 62 46 52 59 
1.25 33 28 28 26 30 31 23 34 31 33 
0.625 20 17 17 17 16 18 18 18 19 19 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All porcine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition. 
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Table 36 
THE INHIBITION OF FACTOR XA BY VARIOUS BOVINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP) 
AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 84 85 84 84 83 84 85 85 85 83 
5 66 66 62 58 74 64 65 66 69 77 
2.5 46 48 38 52 53 46 51 53 49 54 
1.25 22 23 31 27 30 30 27 33 31 32 
0.625 11 12 15 14 14 15 10 19 15 15 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All bovine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition. 
 
 
 
 
 
 
137 
 
Table 37 
THE INHIBITION OF FACTOR XA BY VARIOUS OVINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP) AS 
MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 95 96 96 95 95 95 95 94 97 97 
5 88 93 92 91 89 83 88 82 90 89 
2.5 68 67 66 68 70 62 59 67 64 62 
1.25 36 35 32 34 37 31 32 35 33 31 
0.625 19 20 14 16 15 15 12 11 16 16 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All ovine heparin 
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition. 
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TABLE 38 
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS PORCINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) 
% Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 84 83 84 86 88 86 85 83 83 84 
5 83 83 82 80 85 84 79 80 70 82 
2.5 76 71 66 70 77 64 67 66 68 74 
1.25 58 53 58 56 50 56 54 54 49 59 
0.625 53 51 52 47 41 49 39 46 49 54 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All porcine 
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.  
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TABLE 39 
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS BOVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 80 81 81 82 79 81 77 84 79 84 
5 78 77 77 79 72 77 70 81 72 79 
2.5 57 59 57 51 58 51 51 51 56 54 
1.25 37 33 42 37 41 36 42 42 44 43 
0.625 26 26 20 20 20 25 22 31 24 21 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All bovine 
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.  
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TABLE 40 
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS OVINE HEPARIN BATCHES IN BLOOD BANK 
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY 
 
Concentration Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
 (µg/ml) % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. % Inh. 
10 89 88 89 87 87 85 87 90 85 96 
5 85 83 81 80 80 79 81 87 74 82 
2.5 76 74 73 71 65 71 64 70 70 66 
1.25 60 61 63 59 56 54 58 55 53 57 
0.625 55 46 54 55 54 49 52 52 46 51 
0 0 0 0 0 0 0 0 0 0 0 
 
The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All ovine 
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.  
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TABLE 41 
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN BATCHES AS MEASURED BY THE CHROMOGENIC 
ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED KITS 
 
    Anti-Xa assay      
         
Agents 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg 
Porcine Batches 181 188 189 185 192 190 192 195 193 192 
Bovine Batches 118 142 141 146 142 146 136 127 137 143 
Ovine Batches 193 186 184 200 186 194 196 185 190 202 
 
         
 
    Anti-IIa assay      
 
        
Agents 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg U/mg 
Porcine Batches 186 180 174 182 191 191 183 180 182 190 
Bovine Batches 114 139 152 140 140 158 138 136 137 144 
Ovine Batches 189 179 185 196 195 200 182 183 184 183 
 
Comparative USP potencies as measured by the chromogenic anti-Xa and Anti-IIa assays using Hyphen BioMed kits. 
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TABLE 42 
POTENCY COMARISON FOR VARIOUS HEPARIN BATCHES WHEN SUPPLEMENTED IN PURIFIED AT AS 
MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS 
 
   Anti-Xa (IC50 µg/ml)     
       
Agents 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  
Porcine Batches 2.85 2.35 2.41 2.71 1.98 2.33 2.53 2.79 2.64 2.59 
Bovine Batches 4.15 4.18 4.1 3.2 3.1 3.8 3.4 3.9 3.5 3.4 
Ovine Batches 2.15 2.19 1.98 2.4 2.38 1.89 2.14 1.39 2.16 2.1 
 
         
 
   Anti-IIa (IC50 µg/ml)     
       
Agents 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9 Batch 10 
IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  IC50  
Porcine Batches 0.25 0.29 0.31 0.29 0.31 0.32 0.29 0.27 0.28 0.29 
Bovine Batches 0.49 0.46 0.47 0.43 0.36 0.4 0.34 0.34 0.3 0.32 
Ovine Batches 0.27 0.25 0.24 0.29 0.28 0.24 0.25 0.21 0.24 0.25 
 
Comparative IC50 values of various heparin batches when supplemented in AT purified system as measured by the amidolytic 
anti-Xa and anti-IIa assays. All heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. 
Xa, factor Xa; IIa thrombin; AT, antithrombin.  
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A. UV Detector 
 
B. RI Detector 
 
Figure 27.  Elution profiles of various porcine batches as measured by gel permeation 
chromatography (GPC) using the NRC method.  Both the UV 205 nm (A) and RI (B) 
detector methods were used.  Panel A, shows the UV profile whereas the panel B, shows 
the RI profile. 
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A. UV detector 
 
B. RI detector 
 
Figure 28.  Elution profiles of various bovine batches as measured by gel permeation 
chromatography (GPC) using the NRC method.  Both the UV 205 nm (A) and RI (B) 
detector methods were used.  Panel A, shows the UV profile whereas the panel B, shows 
the RI profile. 
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A. UV detector 
 
B. RI detector 
 
Figure 29.  Elution profiles of various ovine batches as measured by gel permeation 
chromatography (GPC) using the NRC method.  Both the UV 205 nm (A) and RI (B) 
detector methods were used.  Panel A, shows the UV profile whereas the panel B, shows 
the RI profile. 
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A. Calibration Curve – UV Detector 
 
B. Calibration Curve - RI Detector  
 
Figure 30. Calibration curves as measured by gel permeation chromatography (GPC) 
using the 13 narrow range calibrators (NRC method).  Both the UV 205 nm (A) and RI 
(B) detector methods were used. Panel A, shows the UV calibration curve whereas the 
panel B, shows the RI calibration curve. 
L
o
g
 M
o
l 
W
t
3.00
3.20
3.40
3.60
3.80
4.00
4.20
4.40
4.60
4.80
Retention Time
26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00
L
o
g
 M
o
l 
W
t
2.80
3.00
3.20
3.40
3.60
3.80
4.00
4.20
4.40
4.60
4.80
Retention Time
26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00
Log Mol Wt = 1.14 – 0.477T + 0.0109T
2
 – 0.0000936T
3
 
R
2
 = 0.998925 
Log Mol Wt = 1.29 – 0.607T + 0.0145T
2
 – 0.000127T
3
 
R
2
 = 0.999169 
  
147 
 
REFERENCES 
 
1. Adkins, J. R., & Hardy, J. D. (1967). Sodium heparin neutralization and the 
anticoagulant effects of protamine sulfate. Archives of Surgery, 94(2), 175-177. 
2. Ahsan, A., Jeske, W., Mardiguian, J., & Fareed, J. (1994). Feasibility study of 
heparin mass calibrator as a GPC calibrator for heparins and low molecular weight 
heparins. Journal of pharmaceutical sciences, 83(2), 197-201. 
3. Ahsan, A., Jeske, W., Hoppensteadt, D., Lormeau, J. C., Wolf, H., & Fareed, J. 
(1995). Molecular profiling and weight determination of heparins and 
depolymerized heparins. Journal of pharmaceutical sciences, 84(6), 724-727. 
4. Barber, A. J., Käser-Glanzmann, R., Jakabova, M., & Lüscher, E. F. (1972). 
Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin 
neutralizing activity (platelet factor 4) released from human blood 
platelets. Biochimica et Biophysica Acta (BBA)-General Subjects, 286(2), 312-
329. 
5. Baroletti, S., Piovella, C., Fanikos, J., Labreche, M., Lin, J., & Goldhaber, S. Z. 
(2008). Heparin-induced thrombocytopenia (HIT): clinical and economic 
outcomes. Thrombosis and haemostasis, 100(6), 1130-1135. 
6. Barritt, D. W., & Jordan, S. C. (1960). Anticoagulant drugs in the treatment of 
pulmonary embolism: a controlled trial. The Lancet, 275(7138), 1309-1312. 
148 
 
 
7. Barrowcliffe, T. W. (1995). Low molecular weight heparin (s). British journal of 
haematology, 90(1), 1-7. 
8. Blombäck, B., Blombäck, M., Lagergren, H., & Olsson, P. (1963). The Heparin 
Co‐Factor Activity in Plasma and its Relation to the Anticoagulant Effect of 
Intravenously Injected Heparin. Acta Physiologica, 58(4), 306-318. 
9. Bray, B., Lane, D. A., Freyssinet, J. M., Pejler, G., & Lindahl, U. (1989). Anti-
thrombin activities of heparin. Effect of saccharide chain length on thrombin 
inhibition by heparin cofactor II and by antithrombin. Biochemical 
Journal, 262(1), 225-232. 
10. Bick, R. L., Frenkel, E. P., Walenga, J., Fareed, J., & Hoppensteadt, D. A. (2005). 
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic 
mechanism of actions, pharmacology, and clinical use. Hematology/oncology 
clinics of North America, 19(1), 1-51. 
11. Casu, B., Guerrini, M., Naggi, A., Torri, G., De-Ambrosi, L., Boveri, G., ... & 
Ronzoni, G. (1995). Differentiation of beef and pig mucosal heparins by NMR 
spectroscopy. Thrombosis and haemostasis, 74(4), 1205. 
12. Casu, B., & Torri, G. (1999). Structural characterization of low molecular weight 
heparins. In Seminars in thrombosis and hemostasis (Vol. 25, pp. 17-25). 
13. Chargaff, E., & Olson, K. B. (1937). Studies on the Chemistry of Blood 
Coagulation VI. Studies on the Action of Heparin and Other Anticoagulants. The 
Influence of Protamine on the Anticoagulant Effect in Vivo. Journal of Biological 
Chemistry, 122(1), 153-167. 
149 
 
 
14. Choay, J., Petitou, M., Lormeau, J. C., Sinay, P., Casu, B., & Gatti, G. (1983). 
Structure-activity relationship in heparin: a synthetic pentasaccharide with high 
affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical 
and biophysical research communications, 116(2), 492-499. 
15. Choay, J. (1989, October). Structure and activity of heparin and its fragments: an 
overview. In Seminars in thrombosis and hemostasis, 15(4), 359-364. 
16. Chong, B. H. (2003). Heparin‐induced thrombocytopenia. Journal of thrombosis 
and haemostasis, 1(7), 1471-1478. 
17. Couch, N. P. (1989). About heparin, or… whatever happened to Jay McLean. 
Journal of vascular surgery, 10(1), 1-8. 
18. Crawley, J. T., & Lane, D. A. (2008). The haemostatic role of tissue factor 
pathway inhibitor. Arteriosclerosis, thrombosis, and vascular biology, 28(2), 233-
242. 
19. Davie, E. W., Fujikawa, K., & Kisiel, W. (1991). The coagulation cascade: 
initiation, maintenance, and regulation. Biochemistry, 30(43), 10363-10370. 
20. Dawes, J., Pumphrey, C. W., McLaren, K. M., Prowse, C. V., & Pepper, D. 
(1982). The in vivo release of human platelet factor 4 by heparin. Thrombosis 
research, 27(1), 65-76. 
21. Dietrich, C. P., Paiva, J. F., Castro, R. A., Chavante, S. F., Jeske, W., Fareed, J., ... 
& Nader, H. B. (1999). Structural features and anticoagulant activities of a novel 
natural low molecular weight heparin from the shrimp Penaeus brasiliensis. 
Biochimica et Biophysica Acta (BBA)-General Subjects, 1428(2), 273-283. 
150 
 
 
22. Eikelboom, J. W., & Hankey, G. J. (2002). Low molecular weight heparins and 
heparinoids. Medical journal of Australia, 177(7), 379-384. 
23. Fareed, J. (1985) Heparin, its fractions, fragments and derivatives. Some newer 
perspectives.  Semin Thromb Hemost, 11(1):1-9. 
24. Fareed, J., Jeske, W., Hoppensteadt, D., Clarizio, R., & Walenga, J. M. (1998). 
Low-molecular-weight heparins: pharmacologic profile and product 
differentiation. The American journal of cardiology, 82(5), 3L-10L. 
25. Fu, L., Li, G., Yang, B., Onishi, A., Li, L., Sun, P., ... & Linhardt, R. J. (2013). 
Structural characterization of pharmaceutical heparins prepared from different 
animal tissues. Journal of pharmaceutical sciences, 102(5), 1447-1457. 
26. Fu, L., Suflita, M., & Linhardt, R. J. (2016). Bioengineered heparins and heparan 
sulfates. Advanced drug delivery reviews, 97, 237-249. 
27. Glimelius, B., Busch, C., & Höök, M. (1978). Binding of heparin on the surface of 
cultured human endothelial cells. Thrombosis research, 12(5), 773-782. 
28. Gomes, W. J., Leal, J. C., Braile, D. M., Guimarães, J. A., Lopes, R. D., Lima, M. 
A., & Nader, H. B. (2016). A Brazilian perspective for the use of bovine heparin in 
open heart surgery. International journal of cardiology, 223, 611-612. 
29. Gray, E., Mulloy, B., & Barrowcliffe, T. W. (2008). Heparin and low-molecular-
weight heparin. THROMBOSIS AND HAEMOSTASIS-STUTTGART-, 99(5), 
807-818.  
30. Griffith, M. J., Noyes, C. M., Tyndall, J. A., & Church, F. C. (1985). Structural 
evidence for leucine at the reactive site of heparin cofactor II. Biochemistry, 
24(24), 6777-6782. 
151 
 
 
31. Guerrini, M., Bisio, A., & Torri, G. (2001). Combined quantitative 1H and 13C 
nuclear magnetic resonance spectroscopy for characterization of heparin 
preparations. In Seminars in thrombosis and hemostasis, 27(5), 473-482. 
32. Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001). Guide to anticoagulant 
therapy: heparin. Circulation, 103(24), 2994-3018. 
33. Hoppensteadt, D. A., Jeske, W., Ahsan, A., Walenga, J. M., & Fareed, J. (1992, 
December). Biochemical and pharmacologic profile of defined molecular weight 
fractions of heparin. In Seminars in thrombosis and hemostasis (Vol. 19, pp. 12-
19). 
34. Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., ... & 
Gent, M. (1986). Continuous intravenous heparin compared with intermittent 
subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New 
England Journal of Medicine, 315(18), 1109-1114. 
35. Jasper, J. P., Zhang, F., Poe, R. B., & Linhardt, R. J. (2015). Stable isotopic 
analysis of porcine, bovine, and ovine heparins. Journal of pharmaceutical 
sciences, 104(2), 457-463. 
36. K. St.Ange, et al. (2016) Analysis of heparins derived from bovine tissues and 
comparison to porcine intestinal heparins. Clinical and Applied Thrombosis and 
Hemostasis, 22, 520-527. 
37. Käser-Glanzmann, R., Jakábová, M., & Lüscher, E. F. (1972). Isolation and some 
properties of the heparin-neutralizing factor (PF4) released from human blood 
platelets. Cellular and Molecular Life Sciences, 28(10), 1221-1223. 
152 
 
 
38. Kaplan, A. P., & Silverberg, M. (1987). The coagulation-kinin pathway of human 
plasma. Blood, 70(1), 1-15. 
39. Kuberan, B., Lech, M. Z., Beeler, D. L., Wu, Z. L., & Rosenberg, R. D. (2003). 
Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. 
Nature biotechnology, 21(11), 1343. 
40. Lane, D. A., Denton, J., Flynn, A. M., Thunberg, L., & Lindahl, U. (1984). 
Anticoagulant activities of heparin oligosaccharides and their neutralization by 
platelet factor 4. Biochemical Journal, 218(3), 725-732. 
41. Li, E. H., Fenton, J. W., & Feinman, R. D. (1976). The role of heparin in the 
thrombin-antithrombin III reaction. Archives of biochemistry and biophysics, 
175(1), 153-159. 
42. Linhardt, R. J., Rice, K. G., Kim, Y. S., Lohse, D. L., Wang, H. M., & 
Loganathan, D. (1988). Mapping and quantification of the major oligosaccharide 
components of heparin. Biochemical Journal, 254(3), 781-787. 
43. Liu, H., Zhang, Z., & Linhardt, R. J. (2009). Lessons learned from the 
contamination of heparin. Natural product reports, 26(3), 313-321. 
44. Lohse, D. L., & Linhardt, R. J. (1992). Purification and characterization of heparin 
lyases from Flavobacterium heparinum. Journal of Biological Chemistry, 267(34), 
24347-24355. 
45. Mackman, N. (2006). Role of tissue factor in hemostasis and thrombosis. Blood 
Cells, Molecules, and Diseases, 36(2), 104-107. 
46. Maddineni, J., Walenga, J. M., Jeske, W. P., Hoppensteadt, D. A., Fareed, J., 
Wahi, R., & Bick, R. L. (2006). Product individuality of commercially available 
153 
 
 
low-molecular-weight heparins and their generic versions: therapeutic 
implications. Clinical and applied thrombosis/hemostasis, 12(3), 267-276. 
47. Marcum, J. A. (2000). The origin of the dispute over the discovery of heparin. 
Journal of the History of Medicine and Allied sciences, 55(1), 37-66. 
48. Maroney, S. A., & Mast, A. E. (2008). Expression of tissue factor pathway 
inhibitor by endothelial cells and platelets. Transfusion and Apheresis Science, 
38(1), 9-14. 
49. Mayo, K. H., & Chen, M. J. (1989). Human platelet factor 4 monomer-dimer-
tetramer equilibria investigated by proton NMR spectroscopy. Biochemistry, 
28(24), 9469-9478. 
50. McLean, J. (1959). The discovery of heparin. Circulation, 19(1), 75-78. 
51. Monakhova, Y. B., & Diehl, B. W. (2015). Combining 1 H NMR spectroscopy 
and multivariate regression techniques to quantitatively determine falsification of 
porcine heparin with bovine species. Journal of pharmaceutical and biomedical 
analysis, 115, 543-551. 
52. Montalescot, G., Zapol, W. M., Carvalho, A., Robinson, D. R., Torres, A., & 
Lowenstein, E. (1990). Neutralization of low molecular weight heparin by 
polybrene prevents thromboxane release and severe pulmonary hypertension in 
awake sheep. Circulation, 82(5), 1754-1764. 
53. Mosesson, M. W. (2005). Fibrinogen and fibrin structure and functions. Journal of 
Thrombosis and Haemostasis, 3(8), 1894-1904. 
154 
 
 
54. Moss, D. W., Schiele, F., Siest, G., & Colinet, E. (1986). Reference materials for 
clinical enzymology: the work of the Community Bureau of Reference of the 
European Community. Clinical chemistry, 32(3), 556-558. 
55. Mourey, L., Samama, J. P., Delarue, M., Choay, J., Lormeau, J. C., Petitou, M., & 
Moras, D. (1990). Antithrombin III: structural and functional aspects. Biochimie, 
72(8), 599-608. 
56. Mulloy, B., Gray, E., & Barrowcliffe, T. W. (2000). Characterization of 
unfractionated heparin: comparison of materials from the last 50 years. 
Thrombosis and haemostasis, 84(6), 1052-1056. 
57. Okajima, Y., Kanayama, S., Maeda, Y., Urano, S., Kitani, T., Watada, M., ... & 
Ijichi, H. (1981). Studies on the neutralizing mechanism of antithrombin activity 
of heparin by protamine. Thrombosis research, 24(1-2), 21-29. 
58. Olson, S. T., Björk, I., Sheffer, R., Craig, P. A., Shore, J. D., & Choay, J. (1992). 
Role of the antithrombin-binding pentasaccharide in heparin acceleration of 
antithrombin-proteinase reactions. Resolution of the antithrombin conformational 
change contribution to heparin rate enhancement. Journal of Biological Chemistry, 
267(18), 12528-12538. 
59. Packham, M. A. (1994). Role of platelets in thrombosis and hemostasis. Canadian 
journal of physiology and pharmacology, 72(3), 278-284. 
60. Petitou, M., Casu, B., & Lindahl, U. (2003). 1976–1983, a critical period in the 
history of heparin: the discoveryof the antithrombin binding site. Biochimie, 85(1), 
83-89. 
155 
 
 
61. Quinsey, N. S., Greedy, A. L., Bottomley, S. P., Whisstock, J. C., & Pike, R. N. 
(2004). Antith rombin: in control of coagulation. The international journal of 
biochemistry & cell biology, 36(3), 386-389. 
62. Razi, N., & Lindahl, U. (1995). Biosynthesis of heparin/heparan sulfate. The D-
glucosaminyl 3-O-sulfotransferase reaction: target and inhibitor saccharides. 
Journal of Biological Chemistry, 270(19), 11267-11275. 
63. Restaino, O. F., Bhaskar, U., Paul, P., Li, L., De Rosa, M., Dordick, J. S., & 
Linhardt, R. J. (2013). High cell density cultivation of a recombinant E. coli strain 
expressing a key enzyme in bioengineered heparin production. Applied 
microbiology and biotechnology, 97(9), 3893-3900. 
64. Rosenberg, R. D. (1975). Actions and interactions of antithrombin and heparin. 
New England Journal of Medicine, 292(3), 146-151. 
65. Rosenberg, R. D., & Damus, P. S. (1973). The purification and mechanism of 
action of human antithrombin-heparin cofactor. Journal of Biological Chemistry, 
248(18), 6490-6505. 
66. Richard Norman BSc, M. (2011). Skill, drive and luck: the discovery and 
development of heparin. Canadian Medical Association. Journal, 183(18), 2139. 
67. Ruiz-Calero, V., Saurina, J., Galceran, T. M., Hernández-Cassou, S., & Puignou, 
L. (2002). Estimation of the composition of heparin mixtures from various origins 
using proton nuclear magnetic resonance and multivariate calibration methods. 
Analytical and bioanalytical chemistry, 373(4-5), 259-265. 
156 
 
 
68. Sakariassen, K. S., Bolhuis, P. A., & Sixma, J. J. (1979). Human blood platelet 
adhesion to artery subendothelium is mediated by factor VIII–von Willebrand 
factor bound to the subendothelium. Nature, 279(5714), 636-638. 
69. Sandset, P. M., Abildgaard, U., & Larsen, M. L. (1988). Heparin induces release 
of extrinsic: Coagulation pathway inhibitor (EPI). Thrombosis research, 50(6), 
803-813. 
70. Spruill, W. J., Wade, W. E., Huckaby, W. G., & Leslie, R. B. (2001). Achievement 
of anticoagulation by using a weight-based heparin dosing protocol for obese and 
nonobese patients. American Journal of Health-System Pharmacy, 58(22), 2143-
2146. 
71. St. Ange, K., Onishi, A., Fu, L., Sun, X., Lin, L., Mori, D., ... & Jeske, W. (2016). 
Analysis of heparins derived from bovine tissues and comparison to porcine 
intestinal heparins. Clinical and Applied Thrombosis/Hemostasis, 22(6), 520-527. 
72. Tollefsen, D. M., & Blank, M. K. (1981). Detection of a new heparin-dependent 
inhibitor of thrombin in human plasma. Journal of Clinical Investigation, 68(3), 
589. 
73. Tollefsen, D. M., Majerus, D. W., & Blank, M. K. (1982). Heparin cofactor II. 
Purification and properties of a heparin-dependent inhibitor of thrombin in human 
plasma. Journal of Biological Chemistry, 257(5), 2162-2169. 
74. Tollefsen, D. M. (1995). Insight into the mechanism of action of heparin cofactor 
II. Thrombosis and haemostasis, 74(5), 1209-1214. 
 
157 
 
 
75. VERHOEVEN, A. J., TYSNES, O. B., AARBAKKE, G. M., COOK, C. A., & 
HOLMSEN, H. (1987). Turnover of the phosphomonoester groups of 
polyphospoinositol lipids in unstimulated human platelets. The FEBS Journal, 
166(1), 3-9. 
76. Walenga, J. M., & Hoppensteadt, D. A. (2004, December). Monitoring the new 
antithrombotic drugs. In Seminars in thrombosis and hemostasis (Vol. 30, No. 06, 
pp. 683-695). Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh 
Avenue, New York, NY 10001, USA. 
77. Walenga, J. M., Petitou, M., Samama, M., Fareed, J., & Choay, J. (1988). 
Importance of a 3-0-sulfate group in a heparin pentasaccharide for antithrombotic 
activity. Thrombosis research, 52(6), 553-563. 
78. Warkentin, T. E. (1998). Heparin-induced thrombocytopenia. Critical Decisions in 
Thrombosis and Haemostasis. BC Decker Inc. Hamilton, Pagg, 100-8. 
79. Weitz, J. I. (1997). Low-molecular-weight heparins. New England Journal of 
Medicine, 337(10), 688-699. 
80. Xu, Y., Chandarajoti, K., Zhang, X., Pagadala, V., Dou, W., Hoppensteadt, D. M., 
... & Severynse-Stevens, D. (2017). Synthetic oligosaccharides can replace animal-
sourced low–molecular weight heparins. Science Translational Medicine, 9(406), 
eaan5954.  
81. Zhou, L., Matsumura, H., Mezawa, M., Takai, H., Nakayama, Y., Mitarai, M., & 
Ogata, Y. (2013). Protamine stimulates bone sialoprotein gene expression. Gene, 
516(2), 228-237. 
 
158 
 
VITA 
 
The author, Ahmed Kouta, was born in Kuwait on March 26, 1983, to Osama Kouta 
and Afaf Ahmed. After finishing high school in 2000, he got a bachelor’s degree in 
pharmaceutical sciences from Cairo University in Egypt between 2001 and 2006. 
  In 2007, he started to pursue a career in the pharmaceutical industry. He worked at 
Sanofi Aventis company for two years. Then, he joined Novartis pharmaceutical company 
for six years. During this period, Ahmed worked in many fields like cardiovascular, 
neuroscience and ophthalmology with responsibilities of product management including 
medical affairs, drug regulatory issues, and marketing matters. He received a master’s in 
business administration (MBA) from Cambridge KIPP Middle East in June 2011. 
Ahmed joined the Department of Molecular Pharmacology and Therapeutics at 
Loyola University Medical center (Maywood, IL) as a graduate student in August 2015. He 
subsequently joined the Hemostasis and Thrombosis Research Laboratory of the Department 
of Pharmacology (under the supervision of Prof. Jawed Fareed). While at Loyola, he had a 
part time research position in the Department of Pathology under the supervision of Dr. 
Hoppensteadt with responsibilities of standardization and cross referencing of drugs as UFHs 
and LMWHs, instrumentations maintenance and routine laboratory operations. 
His master thesis work focused on the diversification of heparins and the structural 
and biological activities of the UFH manufactured from bovine, ovine and porcine sources. 
Besides his main thesis research, Ahmed has also collaborated with other researchers 
159 
 
interested in the diversification of heparins including Prof. Linhardt, Rensselar Polytechnic 
Institute, New York, USA and Prof. Jian Liu, Eshelman School of Pharmacy of the 
University of North Carolina. Ahmed has authored three abstracts, is a coauthor of two 
manuscripts, and has participated in many national and international conferences. After 
completion of his graduate studies, Ahmed will pursue a PhD degree in pharmacology. 
